

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 August 2002 (08.08.2002)

PCT


(10) International Publication Number
WO 02/060914 A2

- (51) International Patent Classification⁷: **C07H 21/00**
- (21) International Application Number: **PCT/US02/03147**
- (22) International Filing Date: 31 January 2002 (31.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/266,402 1 February 2001 (01.02.2001) US
- (71) Applicant (for all designated States except US): **THE GOVERNMENT OF THE UNITED STATES OF AMERICA**, as represented by **THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; National Institutes of Health, Office of Technology Transfer, 6011 Executive Building, Suite 325, Rockville, MD 20852-3804 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **GOTTESMAN, Susan** [US/US]; 6400 Maiden Lane, Bethesda, MD 20817 (US). **STORZ, Gisela** [US/US]; 9012 Grant Street, Bethesda, MD 20817 (US). **REPOILA, Francis** [FR/US]; 5015 Battery Lane, Apt. 602, Bethesda, MD 20814 (US). **WASSARMAN, Karen** [US/US]; 9918 Thornwood Road, Kensington, MD 20895 (US). **ROSENOW, Carsten** [DE/US]; 105 Livorno Way, Redwood Shores, CA 94065 (US).
- (74) Agent: **ALTMAN, Daniel, E.**; Knobbe, Martens, Olson And Bear, LLP, 620 Newport Center Drive, 16th Floor, Newport Beach, CA 92660 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), DE (utility model), DK (utility model), DM, DZ, EC, EE (utility model), ES, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— of inventorship (Rule 4.17(iv)) for US only
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IDENTIFICATION OF NEW SMALL RNAs AND ORFS E. COLI AS MEDIATORS OF CELL AND INTERCELL REGULATION

rprA

>



(57) Abstract: The invention relates to new small RNAs and ORFs of E. coli as mediators of cell and intercell regulation.

WO 02/060914 A2

**IDENTIFICATION OF NEW SMALL RNAs AND ORFs OF *E. COLI* AS
MEDIATORS OF CELL AND INTERCELL REGULATION**

Field of the Invention

5 The invention relates to new small RNAs and ORFs of *E. coli* as mediators of cell and intercell regulation.

Background of the Invention

 In the last few years, the importance of regulatory small RNAs (sRNAs) as mediators of a number of cellular processes in bacteria has begun to be recognized.

10 Although instances of naturally occurring antisense RNAs have been known for many years, the participation of sRNAs in protein tagging for degradation, modulation of RNA polymerase activity, and stimulation of translation are relatively recent discoveries (see Wassarman, K.M. *et al.* 1999 *Trends Microbiol* 7:37-45 for review; Wassarman, K.M. and Storz, G. 2000 *Cell* 101:613-623). These findings have raised questions about how

15 extensively sRNAs are used, what other cellular activities might be regulated by sRNAs, and what other mechanisms of action exist for sRNAs. In addition, prokaryotic sRNAs appear to target different cellular functions than their eukaryotic counterparts that primarily act during RNA biogenesis. It is unclear whether this difference between prokaryotic and eukaryotic sRNAs is accurate or stems from the incompleteness of current knowledge.

20 Implicit in these questions is the question of how many sRNAs exist in a given organism and whether the current known sRNAs are truly representative of sRNA function in general.

 To date, most known bacterial sRNAs have been identified fortuitously by the direct detection of highly abundant sRNAs (4.5S RNA, tmRNA, 6S RNA, RNase P RNA, and

25 Spot42 RNA), by the observation of an sRNA during studies on proteins (OxyS RNA, Crp Tic RNA, CsrB RNA, and GcvB RNA) or by the discovery of activities associated with overexpression of genomic fragments (MicF RNA, DicF RNA, DsrA RNA, and RprA RNA) (Okamoto, K. and Freundlich, M. 1986 *PNAS USA* 83:5000-5004; Bhasin, R.S. 1989 Studies on the mechanism of the autoregulation of the *crp* operon of *E. coli* K12 In: Dept.

30 of Biochemistry and Cell Biology, State University of New York at Stonybrook; Urbanowski, M.L. *et al.* 2000 *Mol Microbiol* 37:856-868; Wassarman, K.M. and Storz, G.

2000 *Cell* 101:613-623; Majdalani, N. *et al.* 2001 *Mol Microbiol* 39:1382-1394; for review see Wassarman, K.M. *et al.* 1999 *Trends Microbiol* 7:37-45). None of the *E. coli* sRNAs were found as a result of mutational screens. This observation may reflect the small target size of genes encoding sRNAs compared to protein genes, or may be a consequence of the regulatory rather than essential nature of many sRNA functions. The complete genome sequence of an organism provides a rapid inventory of most encoded proteins, tRNAs, and rRNAs, but it has not led to the immediate recognition of other genes that are not translated. In particular, new bacterial sRNA genes have been overlooked, as there are no identifiable classes of sRNAs that can be found based solely on sequence determinants.

Segue to the Summary of the Invention

We and others have previously suggested several approaches to look for new sRNAs including computer searching of complete genomes based on parameters common to sRNAs, probing of genomic microarrays, and isolating sRNAs based on an association with general RNA binding proteins (Wassarman, K.M. *et al.* 1999 *Trends Microbiol* 7:37-45; Eddy, S.R. 1999 *Curr Opin Genet Dev* 9:695-699). Using a combination of these approaches, we have identified 17 novel sRNAs; in addition, we have found six small transcripts that contain short conserved open reading frames (ORFs).

Summary of the Invention

A burgeoning list of small RNAs with a variety of regulatory functions has been identified in both prokaryotic and eukaryotic cells. However, it remains difficult to identify small RNAs by sequence inspection. We utilized the high conservation of small RNAs among closely related bacterial species, as well as analysis of transcripts detected by high-density oligonucleotide probe arrays, to predict the presence of novel small RNA genes in the intergenic regions of the *Escherichia coli* genome. The existence of 23 distinct new RNA species was confirmed by Northern analysis. Of these, six are predicted to encode short ORFs, whereas 17 are novel functional small RNAs. Based on the interaction of these small RNAs with the RNA binding protein Hfq, the modulation of *rpoS* expression, and other information, we contemplate these new small RNAs and ORFs of *E. coli* as mediators of cell and intercell regulation. As such, we anticipate their use in the development of diagnostics and in the development of antibiotics.

Brief Description of the Drawings

Figure 1 shows BLAST alignments of representative Ig regions. The indicated Ig regions were used in a BLAST search of the NCBI Unfinished Microbial Genomes database. Each panel shows the summary figure provided by the BLAST program for matches to

5 *Salmonella enteritidis*, *Salmonella paratyphi* A, *Salmonella typhi*, *Salmonella typhimurium* LT2 and *Klebsiella pneumoniae*, three contain known sRNA genes (*rprA*, *csrB*, and *oxyS*), and four contain sRNA candidates (#14, #17, #52, and #36; see Table 1). For each panel, the center numbered line represents the length of the full Ig region; the orientation of flanking genes is given by > (clockwise) or < (counterclockwise). The top hatched line in

10 each panel is the match to *E. coli* (full identity throughout the Ig). The other hatched or double-diagonal lines resulted from the closest matches, and the other lines indicate additional less homologous matches. Location of the conserved region with respect to the borders of the Ig region also was a criterion used for the selection of our candidates; conservation 3' to an ORF or far from the 5' start of an ORF was considered more likely to

15 encode an sRNA. Note that the conservation within the Ig region encoding *oxyS* might be interpreted as a leader sequence based on location relative to the start of the flanking gene (*oxyR*). However, the conservation extends for 185 nt, and therefore candidate regions in our search in which the conservation was near the start of an ORF but was longer than 150 nt were considered further.

20 **Figure 2** is the expression profile across high-density oligonucleotide arrays for representative Ig regions. Probe intensities are shown for the indicated Ig regions (solid bars) and the flanking ORFs (hatched bars), calculated from the perfect match minus the mismatch intensities. All negative differences were set to zero. The data shown are for one experiment using cDNA probes, but similar results were seen in the duplicate experiment

25 and with directly labeled RNA probes. The Ig regions and each flanking gene generally contain 15 interrogating probes. Upward bars correspond to genes transcribed on the Watson (W, clockwise) strand and downward bars correspond to genes transcribed on the Crick (C, counterclockwise) strand. The C strand signal for the *CsrB* Ig region corresponds well with the known location of the *csrB* gene. Similarly for the *RprA* Ig region, the W

30 strand signal corresponds with the location of the *rprA* gene, but only one probe is positive. The W strand signal for #14 and the C strand signal for #17 overlap well with the

conserved regions shown in the BLAST analysis in Figure 1. #36 was chosen for further analysis because of the strong C strand signal; both flanking ORFs are on the W strand. For #52, low levels of expression were seen on both strands; the very low level for probes in the middle of the Ig on the C strand overlapped best with the conserved region found by the BLAST searches (Figure 1).

Figure 3 shows detection of novel sRNAs by Northern hybridization. Northern hybridization using strand specific probes for each candidate was done on RNA extracted from MG1655 cells grown under three different growth conditions: (E), exponential growth in LB medium; (M), exponential growth in M63-glucose medium, and (S) stationary phase in LB medium. Five μ g of total RNA was loaded in each lane. Exposure times were optimized for each panel for visualization here, therefore the signal intensity shown does not indicate relative abundance between sRNAs. Oligonucleotide probes were used for #12, #22, #55-I, #55-I, and #61; RNA probes were used for all other panels. DNA molecular weight markers (5'-end-labeled *Msp*I digested pBR322 DNA) were run with each set of samples for direct estimation of RNA transcript length. One lane of DNA molecular weight markers are shown for comparison, but these are approximate sizes as there was slight variation in running of gels.

Figure 4 shows results of coimmunoprecipitation of sRNAs with the Hfq protein. (A) Immunoprecipitations using extract from MG1655 cells grown in LB medium in exponential growth ($OD_{600}=0.4$) were done using no antibody (lane 1); 5 μ l of preimmune serum (lane 2); or 0.5, 1, 5, or 10 μ l of hfq antisera (lanes 3-6). Selected RNAs were fractionated on a 10% polyacrylamide urea gel after 3'-end labeling. Asterisks mark RNA bands present in the anti-hfq precipitated samples but not in the preimmune control samples and therefore represent Hfq-interacting RNAs. (B) Immunoprecipitations were done using extract from MG1655 cells grown under three different growth conditions: (E) exponential growth in LB medium; (M) exponential growth in M63-glucose medium, and (S) stationary phase in LB medium. Immunoprecipitations were carried out with 5 μ l of preimmune sera (lane 1) or 5 μ l Hfq antisera (lane 2) and compared to total RNA from 1/10 extract equivalent used in the immunoprecipitations (lane 3). RNAs were fractionated on 10% polyacrylamide urea gels and analyzed by Northern hybridization using RNA probes to previously known sRNAs or our novel RNAs as indicated.

Brief Description of the Sequences

Candidate Number	SEQ ID NO
12	1
14	2
22	3
24	4
25	5
26	6
27	7
31	8
38	9
40	10
41-I	11
41-II	12
52-I	13
52-II	14
55-I	15
55-II	16
61	17
8	18
43	19
9 (nucleotide)	20
9 (amino acid)	21
17 (nucleotide)	22
17 (amino acid)	23
28 (nucleotide)	24
28 (amino acid)	25
36(nucleotide)	26
36 (amino acid)	27
49 (nucleotide)	28
49 (amino acid)	29

50 (nucleotide)	30
50 (amino acid)	31

Detailed Description of the Preferred Embodiment

By "RNA" or "gene product" or "transcription product" is meant the RNA encoded by the *E. coli* gene or RNA substantially homologous or complementary thereto or a derivative or fragment thereof having RNA activity. Encompassed by the definition of "RNA" are variants of RNA in which there have been trivial mutations such as substitutions, deletions, insertions or other modifications of the native RNA. The term "substantial homology" or "substantial identity", when referring to polypeptides or polynucleotides, indicates that the sequence of a polypeptide or polynucleotide in question, when properly aligned, exhibits at least about 30% identity with the sequence of an entire naturally occurring polypeptide or polynucleotide or a portion thereof. Polynucleotides of the present invention which are homologous or substantially homologous to, for example, the polynucleotides of the invention are usually at least about 70% identity to that shown in the Sequence Listing, preferably at least about 90% identity and most preferably at least about 95% identity, or a complement thereof. Any technique known in the art can be used to sequence polynucleotides, including, for example, dideoxynucleotide sequencing (Sanger *et al.* 1977 *PNAS USA* 74:5463-5467), or using the Sequenase™ kit (United States Biochemical Corp.). Homologs of polynucleotides and polypeptides, whether synthetically or recombinantly produced or found in nature, are also encompassed by the scope of the invention, and are herein defined as polynucleotides and polypeptides which are homologous to, respectively, polynucleotides and polypeptides of the invention, or fragments, variants, or complements thereof. Homologous polynucleotides and polypeptides are generally encoded by homologous genes as described above, and retain significant amino acid residue or nucleotide identity to the genes of the invention. Such polypeptides can be expressed by other organisms such as bacteria, yeast and higher order organisms such as mammals. Various methods of determining amino acid residue or nucleotide identity are known in the art. Homologous polynucleotides or polypeptides can be obtained by *in vitro* synthesis by expressing genes derived from other bacteria or by mutagenizing genes of the invention. Also included in the definition of "substantially homologous polynucleotides" would be those polynucleotides which, when annealed under

conditions known in the art, would remain annealed under moderate wash conditions also known in the art (such as washing in 6x SSPE twice at room temperature and then twice at 37°C) (Wahl *et al.* 1987 *Methods in Enzymology* **152** Academic Press Inc., San Diego).

Polynucleotide and polypeptide homology is typically measured using sequence
5 analysis software. See, e.g., Sequence Analysis Software Package of the Genetics
Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue,
Madison, Wis. 53705.

By "polynucleotide" or "nucleic acid" is meant a single- or double-stranded DNA,
genomic DNA, cDNA, RNA, DNA-RNA hybrid, or a polymer comprising purine and
10 pyrimidine bases, or other natural, chemically or biochemically modified or containing
non-natural or derivatized nucleotide bases. The backbone of the polynucleotide can
comprise sugars and phosphate groups (as typically found in RNA or DNA), or modified or
substituted sugar or phosphate groups. Alternatively, the backbone of the polynucleotide
can comprise a polymer of synthetic subunits such as phosphoramidates and is thus a
15 oligodeoxynucleoside phosphoramidate (P-NH₂) or a mixed phosphoramidate-
phosphodiester oligomer (Peyrottes *et al.* 1996 *Nucleic Acids Res* **24**:1841-8; Chaturvedi *et al.* 1996 *Nucleic Acids Res* **24**:2318-23; and Schultz *et al.* 1996 *Nucleic Acids Res* **24**:2966-
73). In another embodiment, a phosphorothiate linkage can be used in place of a
phosphodiester linkage (Braun *et al.* 1988 *J Immunol* **141**:2084-9; and Latimer *et al.* 1995
20 *Mol Immunol* **32**:1057-1064). In addition, a double-stranded polynucleotide can be
obtained from the single-stranded polynucleotide product of chemical synthesis either by
synthesizing the complementary strand and annealing the strands under appropriate
conditions, or by synthesizing the complementary strand *de novo* using a DNA polymerase
with an appropriate primer.

25 A nucleic acid is said to "encode" an RNA or a polypeptide if, in its native state or
when manipulated by methods known to those skilled in the art, it can be transcribed and/or
translated to produce the RNA, the polypeptide or a fragment thereof. The anti-sense
strand of such a nucleic acid is also said to encode the sequence. The polynucleotides of
the present invention comprise those which are naturally-occurring, synthetic or
30 recombinant.

A "recombinant" nucleic acid is one which is chemically synthesized or the product of the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques. Isolated segments within a recombinant nucleic acid can be naturally occurring sequences.

5 By "polynucleotide" or "gene" or "RNA" and the like is meant a polynucleotide encoding or comprising the RNA of the invention, or a homolog, fragment, derivative or complement thereof and having RNA activity as described herein. As is known in the art, a DNA can be transcribed by an RNA polymerase to produce RNA, but an RNA can be reverse transcribed by reverse transcriptase to produce a DNA. Thus a DNA can encode an
10 RNA and vice versa.

The invention also encompasses vectors such as single- and double-stranded plasmids or viral vectors comprising RNA, DNA or a mixture or variant thereof, further comprising a polynucleotide of the invention. A wide variety of suitable expression systems are known in the art and are selected based on the host cells used, inducibility of
15 expression desired and ease of use. The non-transcribed portions of a gene and the non-coding portions of a gene can be modified as known in the art. For example, the native promoters can be deleted, substituted or supplemented with other promoters known in the art; transcriptional enhancers, inducible promoters or other transcriptional control elements can be added, as can be replication origins and replication initiator proteins, autonomously
20 replicating sequence (ARS), marker genes (e.g. antibiotic resistance markers), sequences for chromosomal integration (e.g., viral integration sites or sequences homologous to chromosomal sequences), restriction sites, multiple cloning sites, ribosome-binding sites, RNA splice sites, polyadenylation sites, transcriptional terminator sequences, mRNA stabilizing sequences, 5' stem-loop to protect against degradation, and other elements
25 commonly found on plasmids and other vectors known in the art. Secretion signals from secreted polypeptides can also be included to allow the polypeptide to cross and/or lodge in cell membranes or be secreted from the cell. Such vectors can be prepared by means of standard recombinant techniques discussed, for example, in Sambrook *et al.* 1989 *Molecular Cloning: A Laboratory Manual*, 2nd edition, Cold Spring Harbor Press, Cold
30 Spring Harbor Laboratory, N.Y.; and Ausubel *et al.* (eds.), 1987 *Current Protocols in Molecular Biology*, Greene Publishing Associates, Brooklyn, N.Y.). Many useful vectors

are known in the art and can be obtained from vendors including, but not limited to, Stratagene, New England Biolabs, and Promega Biotech.

An appropriate promoter and other necessary vector sequences are selected so as to be functional in the chosen host. While prokaryotic host cells are preferred, mammalian or
5 other eukaryotic host cells, including, but not limited to, yeast, filamentous fungi, plant, insect, amphibian or avian species, can also be useful for production of the polypeptides of the present invention. See, Kruse *et al.* (eds.) 1973 *Tissue Culture* Academic Press. Examples of workable combinations of cell lines and expression vectors are described in Sambrook *et al.* 1989 or Ausubel *et al.* 1987; see also, e.g., Metzger *et al.* 1988 *Nature*
10 334:31-36. Examples of commonly used mammalian host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cells, and W138, BHK, and COS cell lines, or others as appropriate, e.g., to provide higher expression, desirable glycosylation patterns, etc.

By "bacterial host cell" or "bacteria" or "bacterium" is meant various micro-organism(s) containing at least one chromosome but lacking a discrete nuclear membrane.
15 Representatives include *E. coli*, *Bacillus*, *Salmonella*, *Pseudomonas*, *Staphylococcus* and other *eubacteria*, *archaebacteria*, *chlamydia* and *rickettsia* and related organisms, and the like, and may be spherical, rod-like, straight, curved, spiral, filamentous or other shapes.

Vectors suitable for use with various cells can comprise promoters which can, when appropriate, include those naturally associated with genes of the invention. Promoters can
20 be operably linked to a polynucleotide of the invention.

A nucleic acid sequence is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the gene. Generally, operably linked means that the DNA sequences being linked are
25 contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame.

Promoters can be inducible or repressible by factors which respond biochemically to changes in temperature, osmolarity, carbon source, sugars, etc., as is known in the art. Promoters including, but not limited to, the *trp*, *lac* and phage promoters, tRNA promoters
30 and glycolytic enzyme promoters can be used in prokaryotic hosts. Useful yeast promoters include, but are not limited to, the promoter regions for metallothionein, 3-

phosphoglycerate kinase or other glycolytic enzymes such as enolase or glyceraldehyde-3-phosphate dehydrogenase, enzymes responsible for maltose and galactose utilization. Appropriate foreign mammalian promoters include, but are not limited to, the early and late promoters from SV40 (Fiers *et al.* 1978 *Nature* 273:113-120) and promoters derived from murine Moloney leukemia virus, mouse mammary tumor virus, avian sarcoma viruses, adenovirus II, bovine papilloma virus or polyoma. In addition, the construct can be joined to an amplifiable gene (e.g., DHFR) so that multiple copies of the construct can be made. For appropriate enhancer and other expression control sequences suitable for vectors, see also *Enhancers and Eukaryotic Gene Expression*, Cold Spring Harbor Press: N.Y. 1983.

While expression vectors are preferably autonomously replicating, they can also be inserted into the genome of the host cell by methods known in the art. Expression and cloning vectors preferably contain a selectable marker which is a gene encoding a protein necessary under at least one control for the survival or growth of a host cell transformed with the vector. The presence of this gene ensures the growth of only those host cells which express the inserts. Typical selection genes are known in the art and include, but are not limited to, those which encode proteins that (a) confer resistance to antibiotics or other toxic substances, e.g., ampicillin, neomycin, methotrexate, etc.; (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli. The choice of the proper selectable marker depends on the host cell, as appropriate markers for different hosts are well known.

As one of skill in the art will understand, the choice in construction and arrangement of markers, promoters, origins of replication, etc. in various vectors of the present invention will be dictated by the desired level and timing of expression of RNA of the invention, with the ultimate goal of regulating the production of metabolic compounds in the host cell.

By "protein" or "polypeptide" is meant a polypeptide encoded by the *E. coli* gene of the invention or a polypeptide substantially homologous thereto and having protein activity. Encompassed by the proteins of the invention are variants thereof in which there have been trivial substitutions, deletions, insertions, or other modifications of the native polypeptide which substantially retain protein characteristics, particularly silent or conservative substitutions. Silent nucleotide substitutions are changes of one or more nucleotides which

do not change any amino acid of protein. Conservative substitutions include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Such conservative substitutions are not expected to interfere with biochemical activity, particularly when they occur in structural regions (e.g., alpha helices or beta pleated sheets) of the polypeptide, which can be predicted by standard computer analysis of the amino acid sequence of the protein. Also encompassed by the claimed polypeptides of the invention are polypeptides encoded by polynucleotides which are substantially homologous to a polynucleotide of the invention.

10 Nucleic acids encoding the polypeptides of the present invention include not only native or wild-type sequences but also any sequence capable of encoding the polypeptide, which can be synthesized by making use of the redundancy in the genetic code. Various codon substitutions can be introduced, e.g., silent or conservative changes as discussed above. Due to degeneracy in the genetic code there is some degree of flexibility in the third base of each codon and some amino acid residues are encoded by several different codons. Each possible codon could be used in the gene to encode the protein. While this may appear to present innumerable choices, in practice, each host has a particular preferred codon usage, so that genes can be tailored for optimal translation in the host in which they are expressed. Thus, synthetic genes that encode the proteins of the invention are included in this invention.

Techniques for nucleic acid manipulation are described generally, for example, in Sambrook *et al.* (1989) and Ausubel *et al.* (1987). Reagents useful in applying such techniques, such as restriction enzymes and the like, are widely known in the art and commercially available from vendors including, but not limited to, New England BioLabs, Boehringer Mannheim, Amersham, Promega Biotech, U.S. Biochemicals, New England Nuclear, and a number of other sources.

Nucleic acid probes and primers based on sequences of the invention can be prepared by standard techniques. Such a probe or primer comprises an isolated nucleic acid. In the case of probes, the nucleic acid further comprises a label (e.g., a radionuclide such as ³²P ATP or ³⁵S) or a reporter molecule (e.g., a ligand such as biotin or an enzyme such as horseradish peroxidase). The [³²P]-ATP, [³⁵S]-dATP and [³⁵S]-methionine can be

purchased, for example, from DuPont NEN (Wilmington, Del.). Probes can be used to identify the presence of a hybridizing nucleic acid sequence, e.g., an RNA in a sample or a cDNA or genomic clone in a library. Primers can be used, for example, for amplification of nucleic acid sequences, e.g., by the polymerase chain reaction (PCR). See, e.g., Innis *et al.* 5 (eds.) 1990 *PCR Protocols: A Guide to Methods and Applications*, Academic Press: San Diego. The preparation and use of probes and primers is described, e.g., in Sambrook *et al.* (1989) or Ausubel *et al.* (1987). The genes of homologs of RNA of the invention in other species can be obtained by generating cDNA from RNA from such species using any technique known in the art, such as using Riboclone cDNA Synthesis Systems AMV RT 10 (Promega, Madison, Wis.), then probing such cDNA with radiolabeled primers containing various portions (e.g. 30 or 40 bases long) of the sequences disclosed herein. To obtain homologs of the proteins of the invention, degenerate primers can encode the amino acid sequence of the disclosed *E. coli* protein but differ in codon usage from the sequences disclosed.

15 Antisense and ribozyme nucleic acids capable of specifically binding to sequences of the invention are also useful for interfering with gene expression.

The nucleic acids of the present invention (whether sense or anti-sense, and whether encoding the genes of the invention, or a homolog, variant, fragment or complement thereof) can be produced in large amounts by replication of a suitable recombinant vector 20 comprising DNA sequences in a compatible host cell. Alternatively, these nucleic acids can be chemically synthesized, e.g., by any method known in the art, including, but not limited to, the phosphoramidite method described by Beaucage *et al.* 1981 *Tetra Letts* 22:1859-1862, and the triester method according to Matteucci *et al.* 1981 *J Am Chem Soc* 103:3191, preferably using commercial automated synthesizers. The purification of nucleic 25 acids produced by the methods of the present invention can be achieved by any method known in the art including, but not limited to, those described, e.g., in Sambrook *et al.* (1989), or Ausubel *et al.* (1987). Numerous commercial kits are available for DNA purification including Qiagen plasmid mini DNA cartridges (Chatsworth, Calif.).

The nucleic acids of the present invention can be introduced into host cells by any 30 method known in the art, which vary depending on the type of cellular host, including, but not limited to, electroporation; transfection employing calcium chloride, rubidium chloride

calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; P1 transduction; use of suicide vectors; lipofection; infection (where the vector is an infectious agent, such as a retroviral genome); and other methods. See generally, Sambrook *et al.* (1989), and Ausubel *et al.* (1987). The cells into which these nucleic acids have been introduced also include the progeny of such cells.

A polypeptide "fragment", "portion", or "segment" is a stretch of amino acid residues of at least about 7 to 19 amino acids (or the minimum size retaining an antigenic determinant). A fragment of the present invention can comprise a portion of at least 20 amino acids of the protein sequence, at least 30 amino acids of the protein sequence, at least 40 amino acids of the protein sequence, at least 50 amino acids of the protein sequence, or all or substantially all of the protein sequence. In addition, the invention encompasses polypeptides which comprise a portion of the sequence of the lengths described in this paragraph, which further comprise additional amino acid sequences on the ends or in the middle of sequences. The additional amino acid sequences can, for example, comprise another protein or a functional domain thereof, such as signal peptides, membrane-binding moieties, etc.

A polynucleotide fragment of the present invention can comprise a polymer of at least six bases or basepairs. A fragment of the present invention can comprise at least six bases or basepairs, at least 10 bases or basepairs, at least twenty bases or basepairs, at least forty bases or base pairs, at least fifty bases or basepairs, at least one hundred bases or basepairs, at least one hundred fifty bases or basepairs, at least two hundred bases or basepairs, at least two hundred fifty bases or basepairs, at least three hundred bases or basepairs of the gene sequence. In addition, the invention encompasses polynucleotides which comprise a portion of the sequence of the lengths described in this paragraph, which further comprise additional nucleic acid sequences on the 5' or 3' end or inserted into the sequence. These additional sequences can, for example, encode a coding region of a gene or a functional domain thereof or a promoter.

The terms "isolated", "pure", "substantially pure", and "substantially homogenous" are used interchangeably to describe a polypeptide, or polynucleotide which has been separated from components which naturally accompany it. A monomeric protein or a polynucleotide is substantially pure when at least about 60 to 75% of a sample exhibits a

single polypeptide or polynucleotide sequence. A substantially pure protein or polynucleotide typically comprises about 60 to 90% by weight of a protein or polynucleotide sample, more usually about 95%, and preferably will be over about 99% pure.

5 Protein or polynucleotide purity or homogeneity may be indicated by a number of means, such as polyacrylamide gel electrophoresis of a sample, followed by visualizing a single band upon staining the gel. For certain purposes higher resolution can be provided by using high performance liquid chromatography (HPLC) or other means well known in the art for purification.

10 An RNA or a protein is "isolated" when it is substantially separated from the contaminants which accompany it in its natural state. Thus, a polypeptide which is chemically synthesized or expressed as a recombinant protein, i.e., an expression product of an isolated and manipulated genetic sequence, is considered isolated. A recombinant polypeptide is considered "isolated" even if expressed in a homologous cell type.

15 A polypeptide can be purified from cells in which it is produced by any of the purification methods known in the art. For example, such polypeptides can be purified by immunoaffinity chromatography employing, e.g., the antibodies provided by the present invention. Various methods of protein purification include, but are not limited to, those described in *Guide to Protein Purification*, ed. Deutscher, vol. 182 of *Methods in*
20 *Enzymology* Academic Press, Inc., San Diego, 1990 and Scopes, 1982 *Protein Purification: Principles and Practice* Springer-Verlag, New York.

Polypeptide fragments of the protein of the invention are first obtained by digestion with enzymes such as trypsin, clostripain, or *Staphylococcus* protease, or with chemical agents such as cyanogen bromide, O-iodosobenzoate, hydroxylamine or 2-nitro-5-
25 thiocyanobenzoate. Peptide fragments can be separated by reversed-phase HPLC and analyzed by gas-phase sequencing. Peptide fragments are used in order to determine the partial amino acid sequence of a polypeptide by methods known in the art including but not limited to, Edman degradation.

The present invention also provides polyclonal and/or monoclonal antibodies
30 capable of specifically binding to a polypeptide of the invention, or homolog, fragment, complement or derivative thereof. Antibodies can also be produced which bind specifically

to a polynucleotide of the invention, such as an RNA of the invention or homolog, fragment, complement or derivative thereof, and may be produced as described in, for example, Thiry 1994 *Chromosoma* 103:268-76; Thiry 1993 *Eur J Cell Biol* 62:259-69; Reines 1991 *J Biol Chem* 266:10510-7; Putterman *et al.* 1996 *J Clin Invest* 97:2251-9; and
5 Fournie 1996 *Clin Exp Immunol* 104:236-40. Antibodies capable of binding to polypeptides or polynucleotides of the invention can be useful in detecting protein, in titrating protein, for quantifying protein, for purifying protein or polynucleotide, or for other uses.

For production of polyclonal antibodies, an appropriate host animal is selected,
10 typically a mouse or rabbit. The substantially purified antigen, whether the whole polypeptide, a fragment, derivative, or homolog thereof, or a polypeptide coupled or fused to another polypeptide, or polynucleotide or homolog, derivative, complement or fragment thereof, is presented to the immune system of the host by methods appropriate for the host, commonly by injection into the footpads, intramuscularly, intraperitoneally, or
15 intradermally. Peptide fragments suitable for raising antibodies can be prepared by chemical synthesis, and are commonly coupled to a carrier molecule (e.g., keyhole limpet hemocyanin) and injected into a host over a period of time suitable for the production of antibodies. The sera are tested for immunoreactivity to the protein or fragment. Monoclonal antibodies can be made by injecting the host with the protein polypeptides,
20 fusion proteins or fragments thereof and following methods known in the art for production of such antibodies (Harlow *et al.* 1988 *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratories).

An immunological response is usually assayed with an immunoassay, a variety of which are provided, e.g., in Harlow *et al.* 1988, or Goding 1986 *Monoclonal Antibodies: Principles and Practice*, 2d ed., Academic Press, New York), although any method known
25 in the art can be used.

Monoclonal antibodies with affinities of 10^8 M^{-1} , preferably 10^9 to 10^{10} , or stronger are made by standard procedures as described, e.g., in Harlow *et al.* 1988, or Goding 1986. Briefly, appropriate animals are immunized with the antigen by a standard protocol. After
30 the appropriate period of time, the spleens of such animals are excised and individual spleen cells fused to immortalized myeloma cells. Thereafter the cells are clonally

separated and the supernatants of each clone are tested for their production of an appropriate antibody specific for the desired region of the antigen.

Other suitable techniques of antibody production include, but are not limited to, *in vitro* exposure of lymphocytes to the antigenic polypeptides or selection of libraries of antibodies in phage or similar vectors (Huse *et al.* 1989 *Science* 246:1275-1281).

Frequently, the polypeptides and antibodies are labeled, either covalently or noncovalently, with a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known. Suitable labels include, but are not limited to, radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents, magnetic particles. Also, recombinant immunoglobulins can be produced by any method known in the art.

Identification of Novel Small RNAs Using Comparative Genomics and Microarrays

As a starting point for detecting novel sRNAs in *E. coli*, we considered a number of common properties of the previously identified sRNAs that might serve as a guide to identify genes encoding new sRNAs. We are defining sRNA as relatively short RNAs that do not function by encoding a complete ORF. Of the 13 small RNAs known when this work begun, we were struck by the high conservation of these genes between closely related organisms. In most cases, the conservation between *E. coli* and *Salmonella* was above 85%, whereas that of the typical gene encoding an ORF was frequently below 70%. Conservation tests on random noncoding regions of the genome suggested that extended conservation in intergenic regions was unusual enough to be used as an initial parameter to screen for new sRNA genes. We therefore tested this approach to look for novel sRNAs in the *E. coli* genome.

All known sRNAs are encoded within intergenic (Ig) regions (defined as regions between ORFs). A file containing all Ig sequences from the *E. coli* genome (Blattner, F.R. *et al.* 1997 *Science* 277:1453-1474) was used as a starting point for our homology search. We arbitrarily chose the 1.0- to 2.5-Mb region of the 4.6-Mb *E. coli* genome to test and refine our approach and developed the following steps for searching the full *E. coli* genome.

All Ig regions of 180 nucleotides (nt) or larger were compared to the NCBI Unfinished Microbial Genomes database using the BLAST program (Altschul, S.F. *et al.*

1990 *J Mol Biol* 215:403-410). These 1097 Ig regions were rated based on the degree of conservation and length of the conserved region when compared to the closely related *Salmonella* and *Klebsiella pneumoniae* species. The highest rating was given to Ig regions with a high degree of conservation (raw BLAST score of >80) over at least 80 nt (see below for explanation of ratings). Note that most promoters do not meet these length and conservation requirements. Figure 1 shows a set of BLAST searches for three known sRNAs (RprA RNA, CsrB RNA, OxyS RNA), three Ig regions with high conservation (#14, #17, #52) and one Ig region with intermediate conservation (#36). Some Ig regions had a large number of matches, often to several chromosomal regions of the same organism. These Ig regions were noted and many were found to contain tRNAs, rRNAs, REP, or other repeated sequences. The 40 highly conserved Ig regions containing tRNAs and/or rRNAs were eliminated from our search, as these regions were complicated in their patterns of conservation.

Next the orientation and identity of the ORFs bordering the Ig regions were determined using the Colibri database, an annotated listing of all *E. coli* genes and their coordinates. Inconsistencies between the Colibri database and our original file led to the reclassification of some Ig regions as shorter than 180 nt, and these were not analyzed further. Of the remaining 1006 Ig regions, 13 contained known small RNAs, 295 were in the highest conservation group, 88 showed intermediate conservation, and 610 showed no conservation.

The location of the conservation relative to the orientation of the flanking ORFs was an important consideration in choosing candidates for further analysis. In many cases (132/295 Ig regions), the conserved region was just upstream of the start of an ORF, consistent with conservation of regulatory regions, including untranslated leaders. Cases where the conserved region was >50 nt from an ORF start or extended over more than 150 nt in length (RprA RNA, CsrB RNA, OxyS RNA, #17, and #52 in Fig. 1), or where the bordering ORFs ended rather than started at the Ig region (#14 in Fig. 1), were considered better candidates for novel sRNAs.

Published information on promoters and other known regulatory sites within conserved regions of promising candidates was tabulated and used to eliminate many candidates in which the conservation could be attributed to previously identified promoter

or 5' untranslated leaders. Finally, the remaining candidate regions were examined for sequence elements such as potential promoters, terminators, and inverted repeat regions. We considered evidence for possible stem-loops, in particular those with characteristics of rho-independent terminators, as especially indicative of possible sRNA genes (Table 1).

- 5 Using these criteria, together with microarray expression data (see below), a set of 59 candidates was selected (Table 1). Candidates 1–18 were chosen in the first round of screening of the 1.0- to 2.5-Mb region; some of these candidates would not have met the higher criteria applied to the rest of the genome.

Table 1. sRNA Candidates

No. ^a	Ig Start	Ig Length	Flanking Genes	Strand ^b	Selection Criteria ^c	Microarray Detection ^d	Northern Detection ^e	Interpretation of Conservation ^f
1	1019277	359	<i>ompA/sulA</i>	<<	C (4), S	<	large	known <i>ompA</i> leader
2	1102420	754	<i>csgD/csgB</i>	<>	C (4), L	none	faint large	known <i>csgD</i> leader, promoter
3	1150625	213	<i>fabG/acpP</i>	>>	C* (4), S	>	multiple, 300+ nt	known <i>acpP</i> mRNA & operon
4	1194145	201	<i>ymfC/icd</i>	<>	C* (0), S	>	large	leader
5	1297345	476	<i>adhE/ychE</i>	<>	C (4), L	none	large	known <i>adhE</i> leader
6	1298466	740	<i>yhceE/oppA</i>	>>	C (2), L, S	>	large + faint others	leader, promoter?
7	1328693	376	<i>yciN/topA</i>	<>	C (4)	none	large	known leader, promoter
8	1407055	480	<i>ydaN/dbpA</i>	>>	C (4), L	none	none	predict sRNA
9	1515024	314	<i>ydcW/ydcX</i>	>>	C (4), L, S	<, >	180 nt (<)	mRNA, 31 aa ORF
10	1671526	411	<i>ydgF/ydgG</i>	<>	C (4), L, T	none	none	promoter/leader?
11	1755132	313	<i>pykF/lpp</i>	>>	C (4)	> (rif)	300 nt	known <i>lpp</i> mRNA
12	1762411	550	<i>ydiC/ydiH</i>	<<	C (4), T	none	60 nt (<)	sRNA
13	1860454	341	<i>yeaA/gapA</i>	<>	C (4), S	> (rif)	large	known <i>gapA</i> leader, promoter?
14	2165049	278	<i>yegQ/orgK</i>	><	C (4), L, S	>	86 nt (>)	sRNA
15	2276258	335	<i>yegG/bcr</i>	<<	C (4), L, S	<	large	leader
16	2403093	633	<i>nuoA/lrhA</i>	<<	C (4), L, S	<	large + 300 nt	known processed leader
17	2588726	540	<i>acrD/yffB</i>	>>	C (4), S, I	<	175, 266 nt (<)	mRNA, 19 aa ORF
18	1339749	196	<i>yciM/pyrF</i>	>>	C (3), S*	none	none	promoter/leader?
19	450835	462	<i>cyoA/ampG</i>	<<	C (4), S*	>	faint large	promoter/leader?
20	753692	708	<i>gltA/sdhC</i>	<>	C* (4), S	< (rif)	faint large	known <i>gltA</i> , <i>sdhC</i> leaders
21	986206	605	<i>ompF/asnS</i>	<<	(4), S*, I, P, T	< (rif), >	large	known <i>ompF</i> leader, promoter
22	2651357	823	<i>sseA/sseB</i>	><	C (4), L, S, I, T	> (rif)	320 nt (>)	sRNA
24	3348110	223	<i>elbB/arcB</i>	<<	C* (4), S*	<, >	45 nt (>)	sRNA
25	3578437	332	<i>yhhX/yhhY</i>	<>	C (4), L, P, T	none	90 nt (<)	sRNA
26	3983621	681	<i>aslA/hemY</i>	<<	C (4), T	>	210 nt (>)	sRNA
27	4275510	548	<i>soxR/yjcD</i>	>>	C (4), L, S*, T	<	140 nt (<)	sRNA

No. ^a	Ig Start	Ig Length	Flanking Genes	Strand ^b	Selection Criteria ^c	Microarray Detection ^d	Northern Detection ^e	Interpretation of Conservation ^f
28	4609568	412	<i>osmY/yjiU</i>	>>	C(4), L, S*	< > (rif)	350 nt (>)	mRNA, 53 aa ORF
29	454011	346	<i>bolA/tig</i>	>>	C*(4), S, I	> (rif)	large	leader or operon
30	668152	370	<i>ybeB/cobC</i>	<<	C(4), L, S*, I, P	< > (rif)	large (>)	leader/promoter?
31	887180	180	<i>ybjK/ybjL</i>	><	C(4), L	none	80 nt (<)	sRNA
32	2590752	343	<i>dapE/yjFH</i>	><	C(0), L, S	< >	none	66 aa ORF
33	2967000	684	<i>ygdP/mutH</i>	<>	C*(4)	none	none	promoter/leader?
34	3672003	413	<i>yhjD/yhjE</i>	>>	C*(4)	none	none	promoter/leader?
35	3719676	284	<i>yiaZ/glyS</i>	<<	C(4), L, P	none	large	leader/promoter?
36	3773784	508	<i>mtlR/yibL</i>	>>	(2), S*	< (rif)	500 nt (<)	mRNA, 69 aa ORF
37	4638109	402	<i>yjiY/lasT</i>	>>	C(4), L, P, F	>	none/faint	known <i>arcA</i> leader
38	4048313	614	<i>yihA/yihI</i>	<>	C*(4), S, T	> (rif)	270 nt (>)	sRNA
39	279100	512	<i>afaB/yagB</i>	<<	C(4), L, S*	< >	faint large	IS30, leader/promoter?
40	852161	245	<i>b0816/ybiQ</i>	<>	C(4), L, P	none	205 nt (<)	sRNA
41	2974037	584	<i>aas/galR</i>	<>	C(4), L, S, T	< >	89,83 nt (<)	sRNA
42	2781229	432	<i>pinH/yjiB</i>	<<	C(1), L, T	none	none	not conserved
43	3192539	424	<i>yqiK/yfaE</i>	><	C*(4), L, S	< >	none	predicted sRNA
44	3245066	347	<i>exuR/yqiA</i>	>>	C(4), L	>	none	promoter/leader?
45	3376287	221	<i>rplM/yhcM</i>	<<	C*(4), (S), T	< (rif)	large	leader
46	2531398	386	<i>cysK/ptsH</i>	>>	C(4), S*, T	< > (rif)	large	known <i>ptsH</i> leader
47	4403561	207	<i>purA/yjeB</i>	>>	C(4), S*, I	>	large	leader/promoter?
48	1239170	391	<i>dadX/yegO</i>	><	C(4), L	none	none	IS end
49	1306670	373	<i>cls/kch</i>	<<	C*(4)	none	250 nt (>)	mRNA, 57 aa ORF
50	1620541	446	<i>ydeE/ydeH</i>	><	C(4), L, I	>	185, 220 nt (>)	mRNA, 31 aa ORF
51	1903281	377	<i>yobD/yebN</i>	>>	C(4), L	none	none	promoter/leader?
52	1920997	395	<i>pphA/yebY</i>	<<	C(4), L, S*	< >	275 nt (>), 100 nt (<)	sRNA
53	1932629	237	<i>edd/zwf</i>	<<	C(4)	<	none	promoter/leader?
54	2085091	263	<i>yeeF/yeeY</i>	<<	C(4), T	<	large	leader
55	2151151	740	<i>yegL/yegM</i>	<>	C(4), L	>	143 nt + others (>)	sRNA

No. ^a	Ig Start	Ig Length	Flanking Genes	Strand ^b	Selection Criteria ^c	Microarray Detection ^d	Northern Detection ^e	Interpretation of Conservation ^f
56	2494583	497	<i>ddg/yfdZ</i>	> <	C (4), L	<	none	known ORF
57	3717395	283	<i>yiaG/cspA</i>	> >	C*(4), S*	< >	large	known <i>cspA</i> leader
58	4177159	415	<i>rplA/rplJ</i>	> >	C (4), S*	< >	large	known operon
59	1668974	396	<i>ynfM/asr</i>	> >	(2), S*	<	none	promoter/leader?
60	2033263	591	<i>yedS/yedU</i>	> >	(1), S*	< >	none	not conserved
61	3054807	394	<i>ygfA/serA</i>	> <	(1), D	< >	139 nt (>)	sRNA

^aCandidate numbers. #23 was not analyzed; the region of conservation corresponds to a published leader sequence. Candidate #61 was added because it is homologous to candidate #43 and the duplicated regions within #55 (see Text and Table 2).

- 5 ^bOrientation of flanking genes. > and < denote genes present on the clockwise (Watson) or counterclockwise (Crick) strand of the *E. coli* chromosome, respectively.

- 10 ^cCriteria used for selection of candidates: C, conservation; C*, long conservation; (#), conservation score. Ig regions were assigned scores on the basis of BLAST searches (see text below). #4 and #32 were rerated from 4 (conserved) to 0 on reanalysis of the endpoints of the flanking ORF (#4) and information on an ORF within the Ig region (#32). L, location of conservation either far from 5' end of flanking gene or near 3' end of gene; S, signal detected in microarray experiments; S*, microarray signal on opposite strand to flanking genes; I, inverted repeat; P, predicted promoter; T, predicted terminator; D, duplicated gene.
- 15

^dDetection on high-density oligonucleotide probe arrays. > <, orientation of signal as in *b*. Rif, signals present after 20 min treatment with rifampicin.

- 20 ^eNorthern analysis of RNA extracted from MG1655 cells grown in three conditions (LB medium, exponential phase; minimal medium, exponential phase; LB medium, stationary phase). Strand specific probes were used for sRNA and mRNAs encoding novel ORFs (orientation noted < or > as in *b*); double stranded DNA probes were used for the rest. For #43, bands were originally detected with a double stranded probe, but appear to be from
- 25 homologs (see text). Large, >400 nt.

- ^fInterpretation of high conservation was based on microarray and Northern analyses as well as literature. mRNAs, small RNA transcripts predicted to encode new polypeptides (see text). "known leaders", literature references supported the existence of leaders
- 30 corresponding to conservation. For # 37, conservation is consistent with the leader of the *arcA* gene (Compan, I. and Touati, D. 1994 *Mol Microbiol* 11:955-964). The ORF noted for #56 is described in Seoane, A.S. and Levy, S.B. 1995 *J Bacteriol* 177:530-535; and Bouvier, J. *et al.* 1992 *J Bacteriol* 174:5265-5271; see GenBank entry BAA16347.1. The IS sequence fragment in the conserved region of #48 is homologous to that described by
- 35 McVeigh, A. *et al.* 2000 *Infect Immun* 68:5710-5715. "leaders", a large band on Northern analysis, coupled with conservation near the 5' end of an ORF. "promoter/leader?", absence of RNA signal, coupled with conservation near the 5' end of a gene. "leader/promoter?", RNA signal from microarray or Northern analyses suggested a leader, while the conservation is far from the expected position of a leader. "leader or operon",
- 40 (for #29) microarray analysis suggested a continuous transcript throughout Ig. "predicted sRNAs", (for #8 and #43) Igs contain the hallmarks expected for an sRNA, but RNA transcripts were not detected. Igs encoding sRNAs also may include leaders; this is not included in the conclusion column.

Selecting Candidate Genes by Whole Genome Expression Analysis

In an independent series of experiments, high-density oligonucleotide probe arrays were used to detect transcripts that might correspond to sRNAs from Ig regions. Total RNA isolated from MG1655 cells grown to late exponential phase in LB medium was
5 labeled for probes or used to generate cDNA probes (see text below). From a single RNA isolation each labeling approach was carried out in duplicate and individually hybridized to high-density oligonucleotide microarrays. The high-density oligonucleotide probe arrays used are appropriate for this analysis as they have probes specific for both the clockwise (Watson) and counterclockwise (Crick) strands of each Ig region as well as for the sense
10 strand of each ORF. The resulting data from the four experiments were analyzed to examine global expression within Ig regions, as well as neighboring ORFs.

Our criteria for analyzing the microarray data evolved during the course of this analysis. Stringent criteria (longer transcripts in the Ig region, higher expression levels) identified many of the previously known sRNAs but did not uncover many strong
15 candidates for new small RNAs. More relaxed criteria (shorter transcripts, lower expression levels) gave a very large number of candidates and therefore were not by themselves useful as the initial basis for identifying candidates. However, this data was very useful as an additional criterion for selection of candidate regions based on the conservation approach. Detection of a transcript by microarray on the strand opposite to
20 that of surrounding ORFs was considered a strong indicator of an sRNA (S* in Table 1). Microarray data contributed to the selection of 34 of 59 candidates (Table 1). Examples of the different types of expression observed in microarray experiments are shown in Figure 2. Signal corresponding to CsrB RNA clearly is detected on the Crick (C) strand. #17 and #36 have a transcript in the Ig region on the opposing strand (C) to that for the flanking
25 genes (Watson; W). However, the expression patterns were not as obvious in many cases, either because expression levels were low or because the pattern of expression could be interpreted in a number of ways. For instance, very little expression was detected for RprA RNA encoded on the W strand, and there is unexplained signal detected from the opposite strand of the *rprA* and *csrB* Ig regions. #14 and #52 also had some expression on each
30 strand (Figure 2). #14 proved to express a small RNA from the Watson strand, while #52 expresses sRNAs from each strand (see below and Table 2).

Given that a number of the known sRNAs are relatively stable, we tested whether selection for stable RNAs might allow the microarray data to be more useful for *de novo* identification of sRNA candidates. The transcription inhibitor rifampicin was added to cells for 20 min prior to harvesting the RNA with the intention of enriching for stable
5 RNAs. Many of the known sRNAs can be detected after the rifampicin treatment. Of the 59 candidates in Table 1 twelve retained a hybridization signal (marked rif in Table 1), and four of these proved to correspond to small transcripts (see below). Other rif resistant transcripts detected in Ig regions appeared to be due to highly expressed leaders.

Table 2. Novel sRNAs and Predicted Small ORFs^a

No.	Gene	Minute	RNA Size ^{b,c,d}	Strand ^e	Expression ^f	Hfq Binding ^g	Effect on <i>rpoS-lacZ</i> ^h		Other Information ^j
							S	M	
12	<i>rydB</i>	38	60 ^b	<<<	M>>>S>E	NT	0.4	1.0	
14	<i>ryeE</i>	47	86 ^b	>><	E, S>M	+(E)	0.25	1.2	bordered by cryptic prophage
22	<i>ryjA</i>	57	320 ^c	>><	E, M	NT	NT	NT	PAIR3 (Rudd, K.E. 1999 Res Microbiol 150:653-664)
24	<i>ryhA</i>	72	45 ^b	<><	S>>>M>E	+(S)	1.0	1.9	105, 120 nt, present S>>M>E 105 nt binds Hfq (+, S)
25	<i>ryhB</i>	77	90 ^b	<<>	M>>>S	+(M)	1.2	0.4	multicopy plasmid restricts growth on succinate
26	<i>ryiA</i>	86	210 ^b	<><	E>M, S	+(E)	0.9	1.5	155 nt, present M>E, S
27	<i>ryjA</i>	92	140 ^b	><>	S>>>M	-(S)	NT	NT	
31	<i>rybB</i>	19	80 ^b	><<	S>>>M	+(S)	1.0	2.3	
38	<i>ryiB</i>	87	270 ^b	<>>	M>S>>>E	-(M)	1.0	1.6	CsrC (Romeo, pers. commun.)
40	<i>rybA</i>	18	205 ^b	><>	S>M>E	-(S)	1.2	1.5	ladder up from 255, 300 nt, present S>M>E
41-I	<i>rygA</i>	64	89 ^b	<<>	S>>>M, E	+(S)	1.3 ⁱ	1.7 ⁱ	PAIR2 (Rudd, K.E. 1999 Res Microbiol 150:653-664)
41-II	<i>rygB</i>	64	83 ^b	<<>	S, E>M	+(S)	1.3 ⁱ	1.7 ⁱ	PAIR2 (Rudd, K.E. 1999 Res Microbiol 150:653-664)
52-I	<i>ryeA</i>	41	275 ^b	<><	M>E>S	-/+ (M)	1.1 ⁱ	1.0 ⁱ	148, 152, 180 nt (+ others), present M, S
52-II	<i>ryeB</i>	41	100 ^b	<<<	S>>>M	+(S)	1.1 ⁱ	1.0 ⁱ	70 nt, present S>>M
55-I	<i>ryeC</i>	46	143 ^c 107 ^c	<>>	S>M>E M>E, S	NT	1.2	1.6	QUAD1a (Rudd, K.E. 1999 Res Microbiol 150:653-664)

55-II	<i>ryeD</i>	46	137 ^c 102 ^c	< > >	M > E > S M > E	NT	NT	NT	QUAD1b (Rudd, K.E. 1999 Res Microbiol 150:653-664)
61	<i>rygC</i>	65	139 ^c 107 ^c	> > <	S >> M > E S, M > E	NT	NT	NT	QUAD1c (Rudd, K.E. 1999 Res Microbiol 150:653-664)
8	<i>rydA</i>	30	139 ^d	> (>) >	none	NT	NT	NT	Expression not detected; predicted sRNA
43	<i>rygD</i>	69	143 ^d	> (<) <	none	NT	NT	NT	QUAD1d (Rudd, K.E. 1999 Res Microbiol 150:653-664) Expression not detected
9	<i>yncL</i>	32	180 ^b	> < >	S > M > E	+/- (S)	NT	NT	31 aa ORF
17	<i>ypfM</i>	55	266 ^b	> < >	E >> M	-/+ (E)	2.0	1.5	19 aa ORF 175 nt, present E, M
28	<i>yfiA</i>	99	305 ^b	> > >	S > M	NT	NT	NT	53 aa ORF
36	<i>yibT</i>	81	500 ^b	> < >	S >> E, M	NT	1.3	1.0	69 aa ORF
49	<i>yciY</i>	28	250 ^b	< > <	E, M	NT	NT	NT	57 aa ORF
50	<i>yneM</i>	35	185 ^b 220 ^b	> > <	S M > E	NT	NT	NT	31 aa ORF

^aTable is divided into three sections: detected sRNAs, predicted sRNAs and detected RNAs predicted to encode small ORFs.

^{b,c,d}RNA sizes estimated from Northern analyses using ^bsingle stranded RNA probes or ^coligonucleotide probes, or ^dfrom predictions resulting from sequence analysis (see text)

5 ^e> < denotes orientation of sRNA and flanking genes as in Table 1.

^fRelative expression in three growth conditions: E, LB medium, exponential phase; M, minimal medium, exponential phase; and S, LB medium, stationary phase.

10 ^gRNA coimmunoprecipitation with Hfq as detected by Northern analysis: +, strong binding (>30% of RNA bound); +/-, weak binding (5-10%); -/+, minimal binding (<5%), and -, no detectable binding. E, M, S refer to cell growth conditions as in *f*. NT, not tested.

15 ^hExpression of *rpoS-lacZ* fusion in the presence of multicopy plasmids carrying intergenic regions. Activity was measured in stationary phase in LB medium (S) or minimal medium (M) and normalized to the activity of the vector control in the same experiment. In parallel experiments, cells carrying the vector alone gave 1.3-2 (S) and 0.7-2.6 (M) units, cells carrying pRS-DsrA plasmid gave a 4.9 fold increase (S) and 12 fold increase (M); cells carrying pRS-RprA plasmid gave 3.1 fold (S) and 3.3 fold (M) increase. Results in table are average of at least three independent assays. Values in bold were considered significantly different from the control. NT, not tested.

20 ⁱ#41 and #52 each express two sRNAs so it is not possible to assign a phenotype to a given small RNA. Thus far there is no evidence for a strong phenotype for either candidate.

^jIncluded is information about additional RNA bands detected in Northern analysis.

Small RNA Transcripts Detected by Northern Hybridization

The final test for the presence of an sRNA gene was the direct detection of a small RNA transcript. The candidates in Table 1 were analyzed by Northern hybridization using
 25 RNA extracted from MG1655 cells harvested from three growth conditions (exponential phase in LB medium, exponential phase in M63-glucose medium, or stationary phase in LB medium). The microarray analysis discussed above used RNA isolated from cells grown to late exponential phase in LB medium, which is intermediate between the two LB growth conditions used for the Northern analysis. Initially, Northern analysis was carried out using
 30 double-stranded DNA probes containing the full Ig region for most candidates. In three cases (#8, #22, and #55) PCR amplification of the Ig region to generate a probe was not successful and therefore oligonucleotide probes were used for Northern analysis. Seventeen candidates gave distinct bands consistent with small RNAs, and one additional candidate gave a somewhat larger RNA, but the location of conservation was not consistent
 35 with a leader sequence for a flanking ORF (#36). In some of these cases, two or more RNA species were detected with a single Ig probe (Table 2, see also Fig. 3). One candidate (#43)

gave a signal with the double stranded DNA probe, but contains regions duplicated elsewhere in *E. coli* that probably account for this signal (see below). Of the remaining 41 candidates, 17 gave no detectable transcript. These Ig regions could encode sRNAs expressed only under very specific growth conditions. For instance, #8 has all the sequence hallmarks of an sRNA gene (a well-conserved region preceded by a possible promoter and ending with a terminator), but has not been detected. Alternatively, the observed conservation could be due to nontranscribed regulatory regions. Fairly large RNAs were detected for another 24 candidates. Given the size of these transcripts together with data on the orientation of flanking genes and the location of conserved regions, it is likely these are leader sequences within mRNAs (Table 1).

For candidates expressing RNAs not expected to be 5' untranslated leaders, Northern analysis was carried out with strand-specific probes to determine gene orientation (Fig. 3). For many of the candidates, we used sequence elements (see below) as well as expression information from the microarray experiments to predict which strand was most likely expressed; both strands were tested when predictions were unclear. The results from the strand-specific probes generally agreed with predictions and were used to estimate the RNA size (Table 2). Interestingly, in one case there is an sRNA expressed from both the W and C strand within the Ig (#52; Fig. 3). For #12, although no sRNA had been detected using a double stranded DNA probe, the presence of a potential terminator and promoter remained suggestive of the presence of an sRNA gene. Therefore, oligonucleotide probes also were used in Northern analysis of this candidate, and a small RNA transcript was detected (Fig. 3; Table 1).

Examination of expression profiles of the RNAs under different growth conditions gave an indication of specificity of expression. Some candidates were detected under all three growth conditions; others were preferentially expressed under one growth condition (Fig. 3; Table 2). For instance, #25 was present primarily during growth in minimal medium, consistent with the absence of detection in the whole genome expression experiment, which analyzed RNA isolated from cells grown in rich medium.

Sequence Predictions of sRNA Genes and ORFs

For the candidates expressing small RNA transcripts, the conserved sequence blocks (contigs) from *K. pneumoniae*, the highest conserved *Salmonella* species, and in a

few cases *Yersinia pestis*, were selected from the NCBI Unfinished Microbial Genome database and aligned with the *E. coli* Ig region using GCG Gap (Devereux, J. *et al.* 1984 *Nucleic Acids Res* 12:387-395). Multiple alignments were assembled by hand, and the conserved regions were examined for likely promoters and terminators and other conserved structures. Information from the alignments, together with results from strand-specific Northern and microarray expression analyses, allowed assignments of gene orientation, putative regulatory regions, and RNA length from the predicted starting and ending positions. Where a terminator sequence was very apparent (13 of 19 candidates), transcription was assumed to end at the terminator, and the observed size of the transcript was used to help identify possible promoters. The identification of promoters and terminators was less definite when there was only one species with conservation to *E. coli*.

As the alignments were assembled, the pattern of conservation in some cases was reminiscent of patterns expected from ORFs, with higher sequence variation in positions consistent with the third nucleotide of codons. GCG Map (Devereux, J. *et al.* 1984 *Nucleic Acids Res* 12:387-395) was used to predict translation in all frames for all of the candidate small RNAs. In six cases, the conservation and translation potential suggested the presence of a short ORF. In these cases, a ribosome-binding site and the potential ORF were well conserved, with the most variation in the third position of codons, but other elements of the predicted RNA were less well conserved. For example, #17 expresses an RNA of about 266 nt, containing a predicted ORF of only 19 amino acids. Within the predicted Shine-Delgarno sequence and ORF, only 9/80 positions showed variation for either *Klebsiella* or *Salmonella*, while the overall RNA is less than 60% conserved. We predict that for #17, as well as five others (Table 2), the detected RNA transcript is functioning as an mRNA, encoding a short, conserved ORF. An evaluation of both the new predicted ORFs and the untranslated sRNAs with GLIMMER, a program designed to predict ORFs within genomes, gave complete agreement with our designations (Delcher, A.L. *et al.* 1999 *Nucleic Acids Res* 27:4636-4641).

We have assigned gene names to all candidates that we have confirmed are expressed as RNAs (see Table 2). The genes we predict to encode ORFs were given names according to accepted practice for ORFs (Rudd, K.E. 1998 *Microbiol Mol Biol Rev* 62:985-1019). The genes that express sRNAs without evidence of conserved ORFs were named

with a similar nomenclature: *ryx*, with *ry* denoting RNA and *x* indicating the 10 min interval on the *E. coli* genetic map.

We noted one instance of overlap in sequence between our new sRNAs. The conserved region within #43 is highly homologous to a duplicated region within #55, as well as to a fourth region of the chromosome within a more poorly conserved Ig (#61 in Table 1). This repeated region was previously denoted the QUAD repeat and suggested to encode sRNAs (Rudd, K.E. 1999 *Res Microbiol* 150:653-664). Each of the QUAD repeats contains a short stretch homologous to boxC, a repeat element of unknown function present in 50 copies or more within the genome of *E. coli* (Bachelier, S. *et al.* 1996 Repeated Sequences In: *Escherichia coli and Salmonella: Cellular and Molecular Biology* eds. F.C. Neidhardt, *et al.* pp. 2012-2040 American Society for Microbiology, Washington, D.C.). Rudd also has detected transcripts from the QUAD regions. To determine which of the four QUAD genes was being expressed, we designed oligonucleotide probes unique for each of the four repeats. These oligonucleotide probes demonstrated expression for three of the four QUAD genes (#55-I, #55-II, and #61); furthermore, each gave two RNA bands (Fig. 3; Table 2). No signal was detected for the fourth repeat (#43). The #41 Ig region encodes another pair of repeats, PAIR2 (Rudd, K.E. 1999 *Res Microbiol* 150:653-664), and we observed two RNA species, suggesting that each of the repeats may be transcriptionally active. Finally, another repeat region noted by Rudd, PAIR3, is encoded by the #22 Ig region.

Many sRNAs Bind Hfq and Modulate *rpoS* Expression

Hfq is a small, highly abundant RNA-binding protein first identified for its role in replication of the RNA phage Q β (Franze de Fernandez, M. *et al.* 1968 *Nature* 219:588-590; reviewed in Blumenthal, T. and Carmichael, G.G. 1979 *Annu Rev Biochem* 48:525-548). Recently, Hfq has been shown to be involved in a number of RNA transactions in the cell, including translational regulation (*rpoS*), mRNA polyadenylation, and mRNA stability (*ompA*, *mutS*, and *miaA*) (Muffler, A. *et al.* 1996 *Genes & Dev* 10:1143-1151; Tsui, H.-C.T. *et al.* 1997 *J Bacteriol* 179:7476-7487; Vytvytska, O. *et al.* 1998 *PNAS USA* 95:14118-14123; Hajndorf, E. and Regnier, P. 2000 *PNAS USA* 97:1501-1505; Vytvytska, O. *et al.* 2000 *Genes & Dev* 14:1109-1118). Three of the known *E. coli* sRNAs regulate *rpoS* expression: DsrA RNA and RprA RNA positively regulate *rpoS* translation, whereas

OxyS RNA represses its translation. In all three cases the Hfq protein is required for regulation (Zhang, A. *et al.* 1998 *EMBO J* 17:6061-6068; Majdalani, N. *et al.* 2001 *Mol Microbiol* 39:1382-1394; Sledjeski, D.D. *et al.* 2001 *J Bacteriol* 183:1997-2005), and binding studies have revealed a direct interaction between Hfq and the OxyS and DsrA
 5 RNAs (Zhang, A. *et al.* 1998 *EMBO J* 17:6061-6068; Sledjeski, D.D. *et al.* 2001 *J Bacteriol* 183:1997-2005).

Given the interaction of the Hfq protein with at least three of the known sRNAs, we asked how many of the newly discovered sRNAs are bound by this protein. Hfq-specific antisera was used to immunoprecipitate Hfq-associated RNAs from extracts of cells grown
 10 under the conditions used for the Northern analysis. Total immunoprecipitated RNA was examined using two methods. First, RNA was 3'-end labeled and selected RNAs were visualized directly on polyacrylamide gels. Under each growth condition, several RNA species co-immunoprecipitated with Hfq-specific sera but not with preimmune sera, which indicates that many sRNAs interact with Hfq (Fig. 4A). Second, selected RNAs were
 15 examined using Northern hybridization to determine whether other known sRNAs and any of our newly discovered sRNAs interact with Hfq. For each sRNA, Hfq binding was examined under growth conditions where the sRNA was most abundant (Fig. 4B; Table 2). sRNAs present in samples using the Hfq antisera but not preimmune sera were concluded to interact with Hfq. Comparison of levels of a selected sRNA relative to the total amount
 20 of that sRNA in the extract revealed that many of the sRNAs bound Hfq quite efficiently (>30% bound) (#14, #24, #25, #26, #31, #41, #52-II, Spot42 RNA, and RprA RNA), but other sRNAs bound Hfq less efficiently (<10% bound) (#9, #17, and #52-I), or not at all (#27, #38, #40, 6S RNA, 5S RNA, and tmRNA) (Fig. 4; Table 2).

As mentioned above, at least three of the known sRNAs that interact with Hfq also
 25 regulate translation of *rpoS*, the stationary phase sigma factor. In light of the fact that many of the new sRNAs also interact with Hfq, we examined whether these new sRNAs affect *rpoS* expression. Plasmids carrying the Ig regions encoding either control sRNAs (pRS-DsrA and pRS-RprA) or many of our novel sRNAs were introduced into an MG1655 Δ lac derivative carrying a *rpoS-lacZ* translational fusion. We then compared expression of the
 30 *rpoS-lacZ* fusion in these cells to cells carrying the control vector by measuring β -galactosidase activity at stationary phase in LB or M63-glucose medium (Table 2). As

expected, overproduction of either DsrA RNA or RprA RNA increased *rpoS-lacZ* expression significantly (Table 2 legend). A number of plasmids (pRS-#24, pRS-#31) led to increased *rpoS-lacZ* expression, whereas others (pRS-#12, pRS-#14, and pRS-#25) led to decreased expression. These results indicate that the corresponding sRNAs may directly regulate *rpoS* expression or indirectly affect *rpoS* expression by altering Hfq activity, possibly by competition. Intriguingly, there is not a complete correlation between Hfq binding and altered *rpoS-lacZ* expression in these studies.

As another strategy in defining possible functions for the sRNAs, we screened strains carrying the multicopy plasmids for effects on growth in LB medium at various temperatures as well as growth in minimal medium containing a number of different carbon sources. pRS-#25 renders cells unable to grow on succinate in agreement with predictions for #25 RNA interaction with *sdh* mRNA (discussed below). We were unable to isolate plasmids carrying the #27 Ig region without mutations, indicating that overproduction of this small RNA may interfere with growth. No other growth phenotypes were observed. A caveat for the interpretation of results with the multicopy plasmids is that they contain the full intergenic region, therefore we cannot rule out effects of sequences outside the sRNA genes but within the intergenic regions.

In summary, a multifaceted search strategy to predict sRNA genes was validated by our discovery of 17 novel sRNAs. Northern analysis determined that 44 of 60 candidate regions express RNA transcripts, some of them expressing more than one RNA species. Of these transcripts, 24 were concluded to be 5' untranslated leaders for mRNAs of flanking genes, and another six are predicted to encode new, short ORFs (Tables 1 and 2). The 17 transcripts believed to be novel, functional sRNAs range from 45 nt to 320 nt in length and vary significantly in expression levels and expression profiles under different growth conditions. More than half of the new sRNAs were found to interact with the RNA-binding protein Hfq, indicating that Hfq binding may be a defining characteristic of a family of prokaryotic sRNAs.

Evaluation of Selection Criteria

Three general approaches for predicting sRNA genes were evaluated in this work. In the primary approach, Ig regions were scored for degree and length of conservation between closely related bacterial species followed by examination of sequence features.

This approach proved to be very productive in identifying Ig regions encoding novel sRNAs in *E. coli*; more than 30% of the candidates selected primarily on the basis of their conservation proved to encode novel small transcripts. The availability of nearly completed genome sequences for *Salmonella* and *Klebsiella* made this approach possible.

- 5 Any organism for which the genome sequences of closely related species are known can be analyzed in this way. Comparative genomics of this sort have been used before to search for regulatory sites (for review, see Gelfand, M.S. 1999 *Res Microbiol* 150:755-771), but have not been employed previously to find sRNAs.

- Although we found the conservation-based approach to be the most productive in
10 identifying sRNA genes, we note a number of limitations to its use. A high level of conservation is not sufficient to indicate the presence of an sRNA gene. Many of the most highly conserved regions, not unexpectedly, were consistent with regulatory and leader sequences for flanking genes. We also did not analyze any Ig regions where conservation was attributable to sources other than an sRNA. For example, potential sRNAs processed
15 from mRNAs, or any sRNAs encoded by the antisense strand of ORFs or leaders, may have been missed in our approach. We made the assumption that Ig regions must be ≥ 180 nt to encode an sRNA of ≥ 60 nt, a 50-60-nt promoter and regulatory region to control expression of the sRNA, as well as regulatory regions for flanking genes. Any sRNA genes in smaller Ig regions would have been overlooked. We also excluded the highly conserved tRNA and
20 rRNA operons from our consideration because of their complexity. It is certainly possible that sRNA genes may be associated with these other RNA genes. In fact, sRNA genes have been predicted to be encoded in at least one tRNA operon. In addition, conservation need not be a property of all sRNAs. We expect sRNAs that play a role in modulating cellular metabolism to be well conserved, as is the case for the previously identified sRNAs.
25 Nevertheless, sRNAs may be encoded within or act upon regions for which there is no homology between *E. coli*, *Klebsiella*, and *Salmonella* (e.g., in cryptic prophages and pathogenicity islands), and they would be missed by this approach. Only one of 24 Ig regions within the e14, CP4-54, or CP4-6 prophages showed conservation. A few of these Ig regions showed evidence of transcription by microarray analysis, and RNAs have been
30 implicated in immunity regulation in phage P4 (Ghisotti, D. *et al.* 1992 *Mol Microbiol* 6:3405-3413), which is related to the prophages CP4-54 and CP4-6. Despite the limitations

listed above, however, we believe the use of conservation provides a relatively quick identification of the majority of sRNAs.

An alternative genomic sequence-based strategy for identifying sRNAs would be to search for orphan promoter and terminator elements as well as other potential RNA structural elements. Potential promoter elements were generally too abundant to be useful predictors without other information on their expected location and orientation. We found sequences predicted to be rho-independent terminators a more useful indicator of sRNAs; such sequences were clearly present for 13/17 of the sRNAs and 3/6 of the new mRNAs. In a number of cases, it appears that the sRNAs share a terminator with a convergent gene for an ORF. In other cases, either no terminator was detected or it appeared to be in a neighboring ORF. A search using promoter and terminator sequences as the requirements for identifying sRNAs might therefore have found two-thirds of the sRNAs described here. Phage integration target sequences also could be scanned for nearby sRNA genes. Many phage *att* sites overlap tRNAs (reviewed in Campbell, A.M. 1992 *J Bacteriol* 174: 7495-7499), and *ssrA*, encoding the tmRNA, has a 3' structure like a tRNA and overlaps the *att* site of a cryptic prophage (Kirby, J.E. *et al.* 1994 *J Bacteriol* 176:2068-2081). In this work, we found that the 3' end and terminator of #14 overlaps the previously mapped phage P2 *att* site (Barreiro, V. and Haggard-Ljungquist, E. 1992 *J Bacteriol* 174:4086-4093). #14 sRNA does not obviously resemble a tRNA, suggesting that the overlap between phage *att* sites and RNA genes extends beyond tRNAs and related molecules and may be common to additional sRNAs.

Our second approach, high-density oligonucleotide probe array expression analysis, proved to be more useful in confirming the presence of sRNA genes first found by the conservation approach than in identifying new sRNA genes *de novo*. Further consideration of the location of microarray signal compared to flanking genes as well as analysis of microarray signals after a variety of growth conditions should expand the ability to detect sRNAs in this manner. Under a single growth condition, signal consistent with the RNA identified by Northern analysis was detected for 5/15 of the Ig regions proven to encode new sRNAs and for 4/6 of the new mRNAs. Thus, a similar analysis of microarray data in nonconserved genomic regions might help in the identification of sRNAs missed by the conservation-based approaches. We predict that sRNAs from any organism expressed at

reasonably high levels under normal growth conditions will be detected by microarrays that interrogate the entire genome, inclusive of noncoding regions.

One clear limitation in detecting sRNAs with microarray or Northern analyses is the fact that some sRNAs may be expressed only under limited growth conditions or at extremely low levels. We chose three growth conditions to scan our samples. While most of the previously known sRNAs were seen under these conditions, OxyS RNA, which is induced by oxidative stress, was not detectable. For a few of our candidates in which no RNA was detected, it is possible that an sRNA is encoded but is not expressed sufficiently to be detected under any of our growth conditions. Another possible limitation of hybridization-based approaches is that highly structured sRNAs may be refractory to probe generation. sRNA transcripts may not remain quantitatively represented after the fragmentation used in the direct labeling approach here. cDNA labeling also may underrepresent sRNAs because they are a small target for the oligonucleotide primers, and secondary structure can interfere with efficiency of extension.

As our third approach, sRNAs were selected on the basis of their ability to bind to the general RNA binding protein, Hfq. Northern analysis revealed that many of our novel sRNAs interact with Hfq. In preliminary microarray analysis of Hfq-selected RNAs to look for additional unknown sRNAs, DsrA RNA, DicF RNA, Spot42 RNA, #14, #24, #25, #31, #41, and #52-II were detected among those RNAs with the largest difference in levels between Hfq-specific sera and pre-immune sera. This preliminary experiment suggests that microarray analysis of selected RNAs will be very valuable on a genome-wide basis. Interestingly, a large number of genes with leaders and a number of RNAs for operons were found to co-immunoprecipitate with Hfq (including the known Hfq target *nlpD-rpoS* mRNA (Brown, L. and Elliott, T. 1996 *J Bacteriol* 178:3763-3770). It seems likely that the subset of sRNAs binding a common protein will represent a subset in terms of function; the sRNAs of known function associated with Hfq in our experiments appear to be those involved in regulating mRNA translation and stability. Other sRNAs have been shown to interact with specific prokaryotic RNA-binding proteins, for example, tmRNA with SmpB (Karzai, A.W. et al. 1999 *EMBO J* 18:3793-3799), and the possibility of other sRNAs interacting with these proteins or other general sRNA-binding proteins should be tested. This approach is adaptable to all organisms, and, in fact, binding to Sm and Fibrillarin

proteins has been the basis for identification of several sRNAs in eukaryotic cells (Montzka, K.A. and Steitz, J.A. 1988 *PNAS USA* 85:8885-8889; Tyc, K. and Steitz, J.A. 1989 *EMBO J* 8:3113-3119).

5 All the criteria we used to identify sRNAs also will detect short genes encoding new small peptides, and we have found six conserved short ORFs. Although our approach was intended to develop methods to identify non-translated genes within the genome, short ORFs also are missing from annotated genome sequences. The combination of a requirement for conservation and/or transcription with sequence predictions for ORFs should add significantly to our ability to recognize short ORFs. Small polypeptides have
10 been shown to have a variety of interesting cellular roles. We expect that the short ORFs we have found are involved in signaling pathways, akin to those of *B. subtilis* peptides that enter the medium and carry out cell-cell signaling (reviewed in Lazazzera, B.A. 2000 *Curr Opin Microbiol* 3:177-182).

Characteristics and Functions of New sRNAs

15 The current work serves as a blueprint for the prediction, detection, and characterization of a large group of novel sRNAs. We have definitive information on characteristics that provide information regarding the cellular roles of these new sRNAs. Several known sRNAs that bind the Hfq protein act via base pairing to target mRNAs. The finding that a number of our new sRNAs bind Hfq indicates a similar mechanism of action
20 for this subset of sRNAs. We searched the *E. coli* genome for possible complementary target sequences and examined phenotypes associated with multicopy plasmids containing new sRNA genes. Intriguingly, #25, an sRNA preferentially expressed in minimal medium, has extended complementarity to a sequence near the start of *sdhD*, the second gene of the succinate dehydrogenase operon. When the #25 Ig region is present on a
25 multicopy plasmid, it interferes with growth on succinate minimal medium (Table 2), consistent with #25 sRNA acting as an antisense RNA for *sdhD*. Complementarity to many target mRNAs was found for a number of other novel sRNAs, confirming the validity of this analysis.

30 As outlined in the evaluation of each of our approaches, we do not expect our searches have been exhaustive. sRNAs also have been detected by others using a variety of approaches. The sRNA encoded by #38 was independently identified as a regulatory RNA

(CsrC RNA; T. Romeo, pers. comm.), and others have found additional sRNAs using variations of the approaches used here (Argaman, L. *et al.* 2001. *Curr. Biol.* in press). Nevertheless, we think it unlikely that there are many more than 50 sRNAs encoded by the *E. coli* chromosome and by closely related bacteria. We expect such sRNAs to be present and playing important regulatory roles in all organisms. Using the approaches described here, it is feasible to search all sequenced organisms for these important regulatory molecules. We anticipate that study of the expanded list of sRNAs in *E. coli* will allow a more complete understanding of the range of roles played by regulatory sRNAs.

EXAMPLE 1

10 Computer Searches

Ig regions are defined here as sequences between two neighboring ORFs. We compared Ig regions of ≥ 180 nt against the NCBI Unfinished Microbial Genomes database (http://www.ncbi.nlm.nih.gov/Microb_blast/unfinishedgenome.html) using the BLAST program (Altschul, S.F. *et al.* 1990 *J Mol Biol* 215:403-410). *Salmonella enteritidis* sequence data were from the University of Illinois, Department of Microbiology (<http://www.salmonella.org>). *Salmonella typhi* and *Yersinia pestis* sequence data were from the Sanger Centre (http://www.sanger.ac.uk/Projects/S_typhi/ and http://www.sanger.ac.uk/Projects/Y_pestis/). *Salmonella typhimurium*, *Salmonella paratyphi*, and *Klebsiella pneumoniae* sequences were from the Washington University Genome Sequencing Center.

Each Ig region was rated based on the best match to *Salmonella* or *K. pneumoniae* species. Ig regions containing previously identified sRNAs were rated 5 (each of them met the criteria to be rated 4). Ig regions were rated 4 if the raw BLAST score was >200 (hatched bars in Fig. 1) or 80-200 (double-diagonal bars in Fig 1) extending for >80 nt; 3 if the raw BLAST score was 80-200 (double-diagonal bar) extending for 60-80 nt; 2 if the raw BLAST score was 50-80 (diagonal bar) extending for >65 nt; and 1 if the raw BLAST score was <50 (diagonal-dash, solid or none) or <65 nt. The location of the longest conserved section(s) within each Ig and the number of matches to the NCBI Unfinished Microbial database were recorded. Note that the computer searches were done from May 2000 to December 2000; more sequences are expected to match as the database continues to expand. The identity and orientation of genes flanking each Ig region were determined

from the Colibri database (<http://genolist.pasteur.fr/Colibri>). Ig regions that the Colibri database predicted to be <180 nt in length and Ig regions containing tRNA and/or rRNAs were rated 0 and removed from further consideration.

Strains and Plasmids

5 Strains were grown at 37°C in Luria-Bertani (LB) medium or M63 minimal medium supplemented with 0.2% glucose and 0.002% vitamin B1 (Silhavy, T.J. *et al.* 1984 *Experiments with gene fusions* Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.) except for phenotype testing of strains carrying multicopy plasmids as described below. Ampicillin (50 µg/ml) was added where appropriate. *E. coli* MG1655 was the parent for all
10 strains used in this study. MG1655 *Alac* (DJ480, obtained from D. Jin, NCI), was lysogenized with a λ phage carrying an *rpoS-lacZ* translational fusion (Sledjeski, D.D. *et al.* 1996 *EMBO J* 15:3993-4000) to create strain SG30013.

To generate clones containing the Ig region of each candidate (pCR-#N where N refers to candidate number; see Table 1), Ig regions were amplified by PCR from a
15 MG1655 colony and cloned into the pCRII vector using the TOPO TA cloning kit (Invitrogen). Oligonucleotides were designed so the entire conserved region and in most cases the full Ig region was included. In a few cases, repeated sequences or other irregularities required a reduction in the Ig regions cloned. See Table 3 for a list of all oligonucleotides used in this paper. Ig regions encoding sRNAs also were cloned into
20 multicopy expression vectors (pRS-#N) in which each Ig region is flanked by several vector-encoded transcription terminators. To generate pRS-#N plasmids, pCR-#N plasmids were digested with *Bam*HI and *Xho*I and the Ig-containing fragments were cloned into the *Bam*HI and *Sal*I sites of pRS1553 (Pepe, C.M. *et al.* 1997 *J Mol Biol* 270:14-25), replacing the *lacZ*-α peptide. To construct pBS-spot42, the Spot42-containing fragment was
25 amplified by PCR from K12 genomic DNA, digested with *Eco*RI and *Bam*HI and cloned into corresponding sites in pBluescript II SK⁺ (Stratagene). All DNA manipulations were carried out using standard procedures. All clones were confirmed by sequencing.

Table 3 Oligonucleotides

Oligo Name	Sequence	SEQ ID NO	Candidate Number
KW-39	GCGCCTCGTTATCATCCAAAATACG	32	#1
KW-40	GTCGCCCAGCCAATGCTTTCAGTCG	33	
KW-41	ATTGATCGCACACCTGACAGCTGCC	34	#2
KW-42	GTTGTCACCCTGGACCTGGTCGTAC	35	
KW-43	TGACCGCGATTTGCACAAAATGC	36	#3
KW-44	ACTCTTAAATTTCTATCAAACTCGC	37	
KW-45	GGTATTTTCAGAGATTATGAATTGCCG	38	#4
KW-46	TCACCTCTCCTTCGAGCGCTACTGG	39	
KW-47	AATGCTCTCCTGATAATGTTAACTT	40	#5
KW-48	GGTTAGCTCCGAAGCAAAAGCCGGAT	41	
KW-49	TAATTCCTTTCAAATGAAACGGAGC	42	#6
KW-50	GGACTCCCTCATTATAATTACTGG	43	
KW-51	CTCCTTAAACAAGGACATTAGTCTACG	44	#7
KW-52	ATTCACCTTACCTAATTTGATTCTTCC	45	
KW-123	CCATCGCTTGACGTTGCATTCACCTGC	46	#8(probes)
KW-124	GTCGGCGTCGTACGAATCAATTGTGC	47	
KW-125	GCACAATTGATTCGTACGACGCCGAC	48	
KW-55	TAAGGATAATATTGCAGATCGTAAG	49	#9
KW-56	ATCATCAAACAGCAACTTGCCC	50	
KW-57	TGTCCTTCTCCTGCAAGAGAATTATT	51	#10
KW-58	GCTAATAATAATGTCTTTTCGCTCC	52	
FR-100	GCTTTTGTGAATTAATTTGTATATCGAAGCG	53	#11
FR-101	TATTAATACCCTCTAGATTGAGTTAATC	54	
FR-102	CGATTTACCTCACTTCATCGCTTTCAG	55	#12
FR-103	TGATCCTGACTTAATGCCGCAAGTTC	56	
FR-104	GCTTATCTCCGGCACTCTCAGTGGCTTAGCTCTTGA AGG	57	(probe)
FR-105	TTGCTCACATCTCACTTTAATCGTGCTC	58	#13
FR-106	ATATTCACCAGCTATTTGTTAGTGAATAAAAGG	59	
FR-107	TGATTAATTTTCGATTATTTTCCCGGATGG	60	#14
FR-108	ATTAGAAACAGGAAGCCCCTCAGTCGAG	61	
FR-109	TTATTTTCCCGGAAGCACATTCAC TTCAC	62	#15
FR-110	TGATCTATTGCACAACGAGGAAGC	63	
FR-111	TGCTTACTCATCAAAAGTAGCGCCAGATTC	64	#16
FR-112	TAATCGACGGACGATAGATAATTCCTG	65	
FR-113	CCAATGTGTGCGCTTTTCAACTTCCG	66	#17
FR-114	CGATTTATGAGAATAAATACTCATTTAAGGGTG	67	
FR-115	AAATCCGACTTTAGTTACAACATAC	68	#18
FR-116	GACCAGACCTTCTTGATGATGGGCAC	69	
KW-69	CGACCTCAATTCCACGGGATCTGG	70	#19
KW-70	ATTTAGCTGTAGTAATCACTCGCCG	71	

Oligo Name	Sequence	SEQ ID NO	Candidate Number
KW-71	GGTCTCCTTAGCGCCTTATTGCG	72	#20
KW-72	CGCCACATGCTGTTCTTATTATCCC	73	
KW-73	TTTATGACACCTGCCACTGCCGTC	74	#21
KW-74	CTGTCAAGTTATCTGTTTGTAAAGTCAAGC	75	
KW-126	GCTGTGAAGCACCTGCGTTGCTCATG	76	#22 (probes)
KW-127	GCTGTGAAACACCTGCATTTACGGCCACGG	77	
KW-128	CCGTGGCCGTAAATGCAGGTGTTTCACAGC	78	
KW-77	CCTTTCGCAATTGACTGAAACAC	79	#24
KW-78	GGCTAGACCGGGGTGCGCG	80	
KW-79	AAGGTGGTTATTTACACCTTAGCG	81	#25
KW-80	GTCCTCTTTGGGGTAAATGTC	82	
KW-81	AATGCTCCGGTTTCATGTCATC	83	#26
KW-82	TAGTTCCTTCTCACCCGGAG	84	
FR-117	CACAAGGGCGCTTTAGTTTGTTCCTG	85	#27
FR-118	ATCCCTGAGAGTTTAATTTTCGTCAAG	86	
KW-85	TAATTCGTCGTAATTCGTCCTCC	87	#28
KW-86	CTCTGCCTTCCTGTTTTGTGTG	88	
FR-119	AAACGCATTTGCAACTGTCGGCGCTTTTCC	89	#29
FR-120	CTTGTTACCTCAAAAAATCACAGTGCTCG	90	
FR-121	GCAGTCGGTGATGCTGGATTGCCCCTG	91	#30
FR-122	GTTTTTTTACGGGTAAGCCGCAACGACCATTG	92	
FR-123	TAGTAGATAAGTTTTAGATAAC	93	#31
FR-124	TAAAACTGAAGTTGCCCTGAAAATG	94	
FR-125	TGATGAGTGGTTCTGCAAGAGG	95	#32
FR-126	TAAAAGACAGATTACCTGGCCTG	96	
FR-127	CGGACTACCTCAAAATAAAGCTTTATATACG	97	#33
FR-128	GTCATGATACCTTGATTAAAAACAAACAGC	98	
FR-129	GGCTATAATGCGCACATAACCTCTTG	99	#34
FR-130	AATCTTTTCTTATTTTTTGGCTAACGAATAGCC	100	
FR-131	GTCCAACTTTTGGGGTCAGTACAACTTTG	101	#35
FR-132	TAATAACGCCGTTATTAAATAGCCTGCC	102	
FR-133	TAAGCAACGTCTGCTTACTGCCCTC	103	#36
FR-134	GTGATGGCTTCTGATAAAGATAAATTTATAGCC	104	
FR-135	TAACAGGCTAAGAGGGGC	105	#37
FR-136	ATTGCCACTCTTCTTGATCAAATAACCG	106	
FR-137	AATGCGTCTGTTGATAATTCAAATTAGTC	107	#38
FR-138	TAGCCGTTTTATTTCAGTATAGATTGCG	108	
KW-89	GTTTCGTCGGTAACCCGTTTCAGC	109	#39
KW-90	ATGGCTTAAAGAGAGGTGCC	110	
KW-91	CGTACTTTAAAGGGAGAATGAC	111	#40
KW-92	GTGCTTCCTCATTATGGTGACG	112	
KW-93	GAATGGAGGGAGATTACACG	113	#41
KW-94	CCTTAGTGGGTAAACGCTTAC	114	

Oligo Name	Sequence	SEQ ID NO	Candidate Number
KW-95	CTTTCAGGCAGCTAAGGAAAG	115	#42
KW-96	CAATATGTATTATTGATTGAGTAAACGGG	116	
KW-97	CCTCTTCCAGGAATAATCCC	117	#43
KW-98	CGGAAAGCGGTTACAGATC	118	
KW-132	CTCGTAAGTTTCGCAGCTTATTA	119	#43 (probe)
KW-99	TGAAATTCCTGTCCGACAGG	120	#44
KW-100	GCACTACCGCAATGTTATTGC	121	
KW-101	GCTTACCCAATAAATAGTTACACG	122	#45
KW-102	TAAAACCTGTCACAAATCACAAA	123	
KW-103	GTGGCCTGCTTCAAACCTTTCG	124	#46
KW-104	GTAAAGTCTAGCCTGGCGGTTTCG	125	
FR-139	TAATTCTGGTACGCCTGGCAGATATTTTGCC	126	#47
FR-140	ATCAACCTCAAAAGGGAAATCGGG	127	
KW-105	TAACTTGTTGTAAGCCGGATCGG	128	#48
KW-106	TGAAGCATCTATCGCCGGTTGCG	129	
KW-107	GATTAGAAATCCTTTTGAAAGCGCATTG	130	#49
KW-108	CTTATTGGGCACCGCAATGG	131	
KW-109	CGAACACAATAAAGATTTAATTCAGCC	132	#50
KW-110	CTGATGCTACTGTGTCAACG	133	
KW-111	AATAATCAGACATAGCTTAGGC	134	#51
KW-112	GCCGTGATGGTTTTCGCGTTC	135	
KW-113	TATTTTCCTCCCGCGCTAAAG	136	#52
KW-114	TTCAGCTGATGACCACCACGCTT	137	
KW-115	GAGTTGTCAGAGCAGGATGATTC	138	#53
KW-116	TATCTGCGCTTATCCTTTATGG	139	
KW-117	CCTTTACGGTGATAACCGTCGCG	140	#54
KW-118	CTGACAAGCCTCTCATTTCTTGTC	141	
KW-119	GAGAATTATCGAGGTCCGGTATC	142	#55
KW-120	CTACGCGTTAGCGATAGACTGC	143	
FR-141	AGGCTTACTAAGAACACCAGGGGGAGGGGAA	144	probe for 55-I
FR-142	AGTCATAAGCTTCCCCGCTTACTAAGACTA	145	probe for 55-II
KW-121	CCTCAAATCGGCCATAATAACC	146	56
KW-122	TAAACACCGTCGTCAGAAATGC	147	
FR-143	TAGACTTTTATCCACTTTATTGCTG	148	#57
FR-144	GTGTGCCCTTCGGCGATATGGCGTG	149	
FR-145	CCTTTACGTGGGCGGTGATTTTGTC	150	#58
FR-146	TAGCTTTGCTCCTGGATGTTTGCC	151	
FR-147	GCTGTAATTTATTTCAGCGTTTGTACATACG	152	#59 (probe)
FR-148	TCAGTCAACTCGCTGCGGCGTGTTAC	153	#60
FR-149	CTTATTGTTGCTTAGTTAGGGTAGTCAC	154	
KW-131	CAGTCAGTCTCAGGGGAGGAGCAATC	155	#61 (probe)

Oligo Name	Sequence	SEQ ID NO	Candidate Number
KW-59	TGAATGCACAATAAAAAAATCCCGACCCCTG	156	For DsrA
KW-60	AGTCGCGCAGTACTCCTCTTACCAG	157	Ig region
KW-63	TAATTTCTCATCAGGCGGCTCTGC	158	for RprA Ig
KW-64	TAACATTATCAGCCTGCTGACGGC	159	region
sp42-5'-1	GGCCGAATTCGTAGGGTACAGAGGTAAG	160	for cloning
sp42-3'-1	GGCCGGATCCGTCATTACTGACTGGGGCGG	161	pBSspot42

RNA Analysis

RNA for Northern analysis was isolated directly from $\sim 3 \times 10^9$ cells in exponential growth ($OD_{600} = 0.2-0.4$) or stationary phase (overnight growth) as described previously (Wassarman, K.M. and Storz, G. 2000 *Cell* 101:613-623). Five- μ g RNA samples were

5 fractionated on 10% polyacrylamide urea gels and transferred to Hybond N membrane as described previously (Wassarman, K.M. and Storz, G. 2000 *Cell* 101:613-623). For Northern analysis of candidate regions, double-stranded DNA probes were generated by PCR from a colony of MG1655 cells or from the pCR-#N plasmids with oligonucleotides used for cloning the pCR-#N plasmids. PCR amplification was done with 52°C annealing

10 for 30 cycles in 1x PCR buffer (1 mM each dATP, dGTP, and dTTP; 2.5 μ M dCTP; 100 μ Ci [α^{32} P] dCTP; 10 ng plasmid; 1 unit taq polymerase) (Perkin Elmer). Probes were purified over G-50 microspin columns (Amersham Pharmacia Biotech) prior to use. Northern membranes were prehybridized in a 1:1 mixture of Hybrisol I and Hybrisol II (Intergen) at 40°C. DNA probes with 500 μ g sonicated salmon sperm DNA were heated

15 for 5 min to 95°C, added to prehybridization solution, and membranes were hybridized overnight at 40°C. Membranes were washed by rinsing twice with 4x SSC/0.1% SDS at room temperature followed by three washes with 2x SSC/0.1% SDS at 40°C. Northern blot analysis using RNA probes was done as described previously (Wassarman, K.M. and Steitz, J.A. 1992 *Mol Cell Biol* 12:1276-1285). RNA probes were generated by *in vitro*

20 transcription according to manufacturer protocols (Roche Molecular Biochemicals) from pCR-#N plasmids linearized with *EcoRV* or *HinDIII* using SP6 RNA polymerase or T7 RNA polymerase, respectively; pBS-6S (pGS0112; Wassarman, K.M. and Storz, G. 2000 *Cell* 101:613-623) or pBS-spot42 were linearized with *EcoRI* using T3 RNA polymerase; pGEM-5S (pG5019; Altuvia, S. *et al.* 1997 *Cell* 90:43-53) or pGEM-10Sa (Altuvia, S. *et al.* 1997 *Cell* 90:43-53) were linearized with *EcoRI* using SP6 RNA polymerase.

25

Oligonucleotide probes were labeled by polynucleotide kinase according to manufacturer protocols (New England Biolabs) using [$\gamma^{32}\text{P}$]ATP (>5000 Ci/mmol; Amersham Pharmacia Biotech). For oligonucleotide probes, Northern membranes were prehybridized in Ultrahyb (Ambion) at 40°C followed by addition of labeled oligonucleotide probe and hybridization overnight at 40°C. Membranes were washed twice with 2x SSC/0.1% SDS at room temperature followed by two washes with 0.1x SSC/0.1% SDS at 40°C for 15 minutes each.

Immunoprecipitation

Immunoprecipitations were carried out using extracts from cells in exponential growth ($\text{OD}_{600} = 0.2\text{-}0.4$) or stationary phase (overnight growth) as described previously (Wassarman, K.M. and Storz, G. 2000 *Cell* 101:613-623), using rabbit antisera against the Hfq protein or preimmune serum. After immunoprecipitation, RNA was isolated from Protein A Sepharose-antibody pellets by extraction with phenol:chloroform:isoamyl alcohol (50:50:1) followed by ethanol precipitation. RNA was examined on gels directly after 3' end labeling or analyzed by Northern hybridization after fractionation on 10% polyacrylamide urea gels as described previously (Wassarman, K.M. and Storz, G. 2000 *Cell* 101:613-623).

rpoS-lacZ Expression

Effects on *rpoS-lacZ* expression by multicopy plasmids containing the novel sRNAs were determined from a single colony of SG30013 transformed with pRS-#N, grown for 18 h in 5 ml of LB-ampicillin medium or M63-ampicillin medium supplemented with 0.2% glucose at 37°C. β -galactosidase activity in the culture was assayed as described previously (Zhou, Y.-N. and Gottesman, S. 1998 *J Bacteriol* 180:1154-1158). The numbers provided in Table 2 were calculated as the ratio between pRS-#N and the pRS1553 vector control.

Phenotype Testing

To test carbon source utilization or temperature sensitivity associated with the multicopy plasmids containing the novel sRNAs, a single colony of MG1655 transformed with a given pRS-#N was grown for 6 hours in 5 ml LB-ampicillin medium at 37°C. Then 10 μl of serial dilutions (10^{-2} , 10^{-4} , and 10^{-6}) were spotted on M63-ampicillin plates containing 0.2% of the carbon source being tested (glucose, arabinose, lactose, glycerol,

ribose, or succinate) and grown at 37°C; or on LB plates incubated at room temperature or 42°C. Plates were analyzed after both 1 and 2 days. Failure to grow in Table 2 indicates an efficiency of plating of $<10^{-3}$.

Microarray Analysis

5 RNA for microarray analysis was isolated using the MasterPure RNA purification kit according to the manufacturer protocols (Epicentre) from MG1655 cells grown to $OD_{600} = 0.8$ in LB medium at 37°C. DNA was removed from RNA samples by digestion with DNase I for 30 min at 37°C. Probes for microarray analysis were generated by one of two methods: direct labeling of enriched mRNA or generation of labeled cDNA.

10 To generate direct labeled RNA probes, mRNA enrichment and labeling was done as described in the Affymetrix expression handbook (Affymetrix). Oligonucleotide primers complementary to 16S and 23S rRNA were annealed to total RNA followed by reverse transcription to synthesize cDNA strands complementary to 16S and 23S rRNA species. 16S and 23S were degraded with RNase H followed by DNase I treatment to remove cDNA
15 and oligonucleotides. Enriched RNA was fragmented for 30 min at 95°C in 1x T4 polynucleotide kinase buffer (New England Biolabs), followed by labeling with γ -S-ATP and T4 polynucleotide kinase and ethanol precipitation. The biotin label was introduced by resuspending RNA in 96 μ l of 30 mM MOPS (pH 7.5), 4 μ l of a 50 mM Iodoacetylbiotin solution, and incubating at 37°C for 1 hr. RNA was purified using the RNA/DNA Mini Kit
20 according to manufacturer protocols (QIAGEN).

To generate cDNA probes, 5 μ g of total RNA was reverse transcribed using the Superscript II system for first strand cDNA synthesis (Life Technologies) and 500-ng random hexamers. RNA and primers were heated to 70°C and cooled to 25°C; reaction buffer was then added, followed by addition of Superscript II and incubation at 42°C. RNA
25 was removed by RNase H and RNase A. The cDNA was purified using the Qiaquick cDNA purification kit (QIAGEN) and fragmented by incubation of up to 5 μ g cDNA and 0.2 U DNase I for 10 min at 37°C in 1x one-phor-all buffer (Amersham-Pharmacia Biotech). The reaction was stopped by incubation for 10 min at 99°C, and fragmentation was confirmed on a 0.7% agarose gel to verify that average length fragments were 50 - 100
30 nt. Fragmented cDNA was 3'-end-labeled with terminal transferase (Roche Molecular

Biochemicals) and biotin-N6-ddATP (DuPont/NEN) in 1x TdT buffer (Roche Molecular Biochemicals) containing 2.5 mM cobalt chloride for 2 hours at 37°C.

Hybridization to microarrays and staining procedures were done according to the Affymetrix expression manual (Affymetrix). The arrays were read at 570 nm with a
5 resolution of 3 µm using a laser scanner.

The expression of genes was analyzed using the Affymetrix Microarray Suite 4.01 software program. Detection of transcripts in intergenic regions was done using the intensities of each probe designed to be a perfect match and the corresponding probe designed to be the mismatch. If the perfect match probe showed an intensity that was 200
10 units higher than the mismatch probe, the probe pair was called positive. Two neighboring positive probe pairs were considered evidence of a transcript. The location and length of the transcripts were estimated based on the first and last identified positive probe pair within an Ig region.

15 While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention. All patents, patent applications and publications referred to above are hereby incorporated by reference.

WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising Candidate #8, or its complement, or its homolog having at least about 95% identity thereto.
2. An isolated polynucleotide comprising Candidate #12, or its complement, or its homolog having at least about 95% identity thereto.
3. An isolated polynucleotide comprising Candidate #14, or its complement, or its homolog having at least about 95% identity thereto.
4. An isolated polynucleotide comprising Candidate #22, or its complement, or its homolog having at least about 95% identity thereto.
5. An isolated polynucleotide comprising Candidate #24, or its complement, or its homolog having at least about 95% identity thereto.
6. An isolated polynucleotide comprising Candidate #25, or its complement, or its homolog having at least about 95% identity thereto.
7. An isolated polynucleotide comprising Candidate #26, or its complement, or its homolog having at least about 95% identity thereto.
8. An isolated polynucleotide comprising Candidate #27, or its complement, or its homolog having at least about 95% identity thereto.
9. An isolated polynucleotide comprising Candidate #31, or its complement, or its homolog having at least about 95% identity thereto.
10. An isolated polynucleotide comprising Candidate #38, or its complement, or its homolog having at least about 95% identity thereto.
11. An isolated polynucleotide comprising Candidate #40, or its complement, or its homolog having at least about 95% identity thereto.
12. An isolated polynucleotide comprising Candidate #41-I, or its complement, or its homolog having at least about 95% identity thereto.
13. An isolated polynucleotide comprising Candidate #41-II, or its complement, or its homolog having at least about 95% identity thereto.
14. An isolated polynucleotide comprising Candidate #43, or its complement, or its homolog having at least about 95% identity thereto.
15. An isolated polynucleotide comprising Candidate #52-I, or its complement, or its homolog having at least about 95% identity thereto.

16. An isolated polynucleotide comprising Candidate #52-II, or its complement, or its homolog having at least about 95% identity thereto.
17. An isolated polynucleotide comprising Candidate #55-I, or its complement, or its homolog having at least about 95% identity thereto.
18. An isolated polynucleotide comprising Candidate #55-II, or its complement, or its homolog having at least about 95% identity thereto.
19. An isolated polynucleotide comprising Candidate #61, or its complement, or its homolog having at least about 95% identity thereto.
20. An isolated polynucleotide comprising Candidate #9, or its complement, or its homolog having at least about 95% identity thereto.
21. An isolated polynucleotide comprising Candidate #17, or its complement, or its homolog having at least about 95% identity thereto.
22. An isolated polynucleotide comprising Candidate #28, or its complement, or its homolog having at least about 95% identity thereto.
23. An isolated polynucleotide comprising Candidate #36, or its complement, or its homolog having at least about 95% identity thereto.
24. An isolated polynucleotide comprising Candidate #49, or its complement, or its homolog having at least about 95% identity thereto.
25. An isolated polynucleotide comprising Candidate #50, or its complement, or its homolog having at least about 95% identity thereto.
26. An isolated polypeptide comprising a polypeptide encoded by Candidate #9, or its homolog having at least about 95% identity thereto.
27. An isolated polypeptide comprising a polypeptide encoded by Candidate #17, or its homolog having at least about 95% identity thereto.
28. An isolated polypeptide comprising a polypeptide encoded by Candidate #28, or its homolog having at least about 95% identity thereto.
29. An isolated polypeptide comprising a polypeptide encoded by Candidate #36, or its homolog having at least about 95% identity thereto.
30. An isolated polypeptide comprising a polypeptide encoded by Candidate #49, or its homolog having at least about 95% identity thereto.

31. An isolated polypeptide comprising a polypeptide encoded by Candidate #50, or its homolog having at least about 95% identity thereto.
32. An isolated antibody that selectively binds Candidate #8.
33. An isolated antibody that selectively binds Candidate #12.
34. An isolated antibody that selectively binds Candidate #14.
35. An isolated antibody that selectively binds Candidate #22.
36. An isolated antibody that selectively binds Candidate #24.
37. An isolated antibody that selectively binds Candidate #25.
38. An isolated antibody that selectively binds Candidate #26.
39. An isolated antibody that selectively binds Candidate #27.
40. An isolated antibody that selectively binds Candidate #31.
41. An isolated antibody that selectively binds Candidate #38.
42. An isolated antibody that selectively binds Candidate #40.
43. An isolated antibody that selectively binds Candidate #41-I.
44. An isolated antibody that selectively binds Candidate #41-II.
45. An isolated antibody that selectively binds Candidate #43.
46. An isolated antibody that selectively binds Candidate #52-I.
47. An isolated antibody that selectively binds Candidate #52-II.
48. An isolated antibody that selectively binds Candidate #55-I.
49. An isolated antibody that selectively binds Candidate #55-II.
50. An isolated antibody that selectively binds Candidate #61.
51. An isolated antibody that selectively binds Candidate #9, or the polypeptide encoded by Candidate #9.
52. An isolated antibody that selectively binds Candidate #17, or the polypeptide encoded by Candidate #17.
53. An isolated antibody that selectively binds Candidate #28, or the polypeptide encoded by Candidate #28.
54. An isolated antibody that selectively binds Candidate #36, or the polypeptide encoded by Candidate #36.
55. An isolated antibody that selectively binds Candidate #49, or the polypeptide encoded by Candidate #49.

56. An isolated antibody that selectively binds Candidate #50, or the polypeptide encoded by Candidate #50.

57. Any of the polynucleotides of claims 1 to 19 or the polypeptides of claims 26 to 31 for use as mediators of cell or intercell regulation.

FIG. 1A

rprA




FIG. 1B

csrB





FIG. 1C

oxyS









FIG. 1F
#36




FIG. 1G
#52




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 2E





FIG. 2F






FIG. 3

FIG. 4A





FIG. 4B



SEQUENCE LISTING

<110> The Government of the United States of America, as represented by
 Secretary, Health and Human Services
 Gottesman, Susan
 Storz, Gisela
 Repoila, Francis
 Wassarman, Karen
 Rosenow, Carsten

<120> IDENTIFICATION OF NEW SMALL RNAs AND
 ORFs

<130> NIH210.001PCT

<150> US 60/266402

<151> 2001-02-01

<160> 161

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 93

<212> DNA

<213> E. Coli

<400> 1

gccccttcaa gagctaagcc actgagagtg ccggagataa gcgccggatg gggtagaaac 60
 ccttaagcct gtgtcgacac gacttaaggg ttt 93

<210> 2

<211> 86

<212> DNA

<213> E. Coli

<400> 2

tcgctgaaaa acataaccca taaaatgcta gctgtaccag gaaccacctc cttagcctgt 60
 gtaatcctcc ttacacgggc ttatatt 86

<210> 3

<211> 307

<212> DNA

<213> E. Coli

<400> 3

actgcggccc tttccgccgt ctgcgaaaacg ggcgctggct ttaggaaagg atgttccgtg 60
 ccgtaaatgc aggtgtttca cagcgcttgc tatcgccgca atatcgccag tgggtgctgtc 120
 gtgatgcggg cttcgcatgg accgcacaaat gaagatacgg tgcttttgta tegtacttat 180
 tgtttctggg gcgctgttaa ccgaggtaaa taataaccgg agtctctccg gcgacaattt 240
 actggtggtt aacaaccttc agagcagcaa gtaagcccga atgcgcacct ttgggcggga 300
 tattttta 307

<210> 4

<211> 65
<212> DNA
<213> E. Coli

<400> 4
acggcgcagc caagatttcc ctggtggttg cgcagtattc gcgcaccccg gtctagccgg 60
ggtca 65

<210> 5
<211> 92
<212> DNA
<213> E. Coli

<400> 5
cgcgatcagg aagaccctcg cggagaacct gaaagcacga cattgctcac attgcttcca 60
gtattactta gccagccggg tgctggcttt tt 92

<210> 6
<211> 211
<212> DNA
<213> E. Coli

<400> 6
aacgagtaga tgctcattcc atctcttatg ttgcgcttag tgccataa actccggaat 60
gacgcagagc cgtttacggg gcttatcgtc cactgacaga tgctcgcttat gcctcatcag 120
acaccatgga cacaacgttg agtgaagcac ccacttggtg tcatacagac ctgttttaac 180
gcctgctccg taataagagc aggcgttttt t 211

<210> 7
<211> 141
<212> DNA
<213> E. Coli

<400> 7
catcaacacc aaccggaacc tccaccacgt gctcgaatga ggtgtgttga cgctcggggga 60
aaccctcctg tgtaccagcg ggatagagag aaagacaaag accggaaaac aaactaaagc 120
gcccttggtg cgcttttagt t 141

<210> 8
<211> 79
<212> DNA
<213> E. Coli

<400> 8
tgccactgct tttctttgat gtccccattt tgtggagccc atcaaccccg ccatttcggt 60
tcaagggtga tgggttttt 79

<210> 9
<211> 272
<212> DNA
<213> E. Coli

<400> 9
tgtttaaaagc aaaggcgtaa agtagcacc c atagagcgag gacgctaaca ggaacaatga 60
ctcaggatga gggtcaggag cgccaggagg cgaagacaga ggattgtcag gaagacaaac 120

```

gtccggagac gtaattaaac ggaaatggaa tcaacacgga ttgttccta aaggaaaaac 180
aggggtgtgtt ggcggcctgc aaggattgta agaccggtta agggttatga gtcaggaaaa 240
aaggcgacag agtaatctgt cgcctttttt ct 272

```

<210> 10

<211> 195

<212> DNA

<213> E. Coli

<400> 10

```

acattgtaaa ccagagttgc gaagggtacaa aaaattaacg ttttagcaat agctatataa 60
tatagcctgt gctatatctg tatgtaatgc aatcatccct caaggatcga cgggatttagc 120
aagtcaggag gtcttatgaa tgagttcaag aggtgtatgc gcgtgttttag tcattctccc 180
tttaaagtac ggtaa 195

```

<210> 11

<211> 82

<212> DNA

<213> E. Coli

<400> 11

```

atcccagagg tattgatagg tgaagtcaac ttcgggttga gcacatgaat tacaccagcc 60
tgcgcagatg cgcaggtttt tt 82

```

<210> 12

<211> 92

<212> DNA

<213> E. Coli

<400> 12

```

atcccagagg tattgattgg tgagattatt cggtaacgctc tcttcgtacc ctgtctcttg 60
caccaacctg cgcgggatgcg cagggttttt tt 92

```

<210> 13

<211> 278

<212> DNA

<213> E. Coli

<400> 13

```

actataaagt cagcgaagga aatgcttctg gcttttaaca gataaaaaga gaccgaacac 60
gattcctgta ttcgggtccag ggaaatggct cttgggagag agccgtgcgc taaaagttgg 120
cattaatgca ggcttagttg ccttgccctt taagaataga tgacgacgcc aggttttcca 180
gtttgcgtgc aaaatgggtca ataaaaagcg tgggtggcat cagctgaaat gttaaaaacc 240
gccggttctg gtgaaagaac tgaggcggtt tttttatt 278

```

<210> 14

<211> 105

<212> DNA

<213> E. Coli

<400> 14

```

agggcaaggc aactaagcct gcattaatgc caacttttag cgcacggctc tctcccaaga 60
gccatttccc tggaccgaat acaggaatcg tgttcggtct ctttt 105

```

<210> 15

<211> 144
<212> DNA
<213> E. Coli

<400> 15
agtgagggtt agggagaggt ttccccctcc ccctggtggt cttagtaagc ctggaagcta 60
atcactaaga gtatcaccag tatgatgacg tgcttcatca taaccctttc cttattaaaa 120
gccctcttct cgggagagg cttt 144

<210> 16
<211> 137
<212> DNA
<213> E. Coli

<400> 16
agtgagggtt gagcgggggt tcccccgccc tggtagtctt agtaagcggg gaagcttatg 60
actaagagca ccacgatgat gagtagcttc atcatgacct tttccttatt tatggccctt 120
tctcgggag gggcttt 137

<210> 17
<211> 112
<212> DNA
<213> E. Coli

<400> 17
aggaacaagg gtaagggagg atttctcccc cctctgattg gctgttaata agctgcgaaa 60
cttacgagta acaacacaaat cagtatgatg acgagcttca tcataaccct tt 112

<210> 18
<211> 139
<212> DNA
<213> E. Coli

<400> 18
cagggcaata tctctcttgc aggtgaatgc aacgtcaagc gatgggctt gcgctccata 60
ttgtcttact tccttttttg aattactgca tagcacaatt gattcgtacg acgccgactt 120
tgatgagtcg gcttttttt 139

<210> 19
<211> 155
<212> DNA
<213> E. Coli

<400> 19
tagagtaaaag gaacaagggt aaggaggat ttctcccccc tctgattggc tgtaataaag 60
ctgcgaaact tacgagtaac aacacaatca gtatgatgac gagcttcac ataacccttt 120
ccttctgtaa ggcccccttc ttggggaggg gcttt 155

<210> 20
<211> 128
<212> DNA
<213> E. Coli

<400> 20
cataggggca atgataaaaag gtggcaaaaa tgaatgtttc cagtagaact gtagtactga 60

taaattttctt tgctgctggt gggttggtta ctcttatctc tatgagattt ggctgggtta 120
 ttgatgt 128

<210> 21
 <211> 31
 <212> PRT
 <213> E. Coli

<400> 21
 Met Asn Val Ser Ser Arg Thr Val Val Leu Ile Asn Phe Phe Ala Ala
 1 5 10 15
 Val Gly Leu Phe Thr Leu Ile Ser Met Arg Phe Gly Trp Phe Ile
 20 25 30

<210> 22
 <211> 84
 <212> DNA
 <213> E. Coli

<400> 22
 ataattataa gagagggttg tatgattgaa cgtgaactgg ggaactggaa agactttatc 60
 gaagttatgc ttcgtaagta attc 84

<210> 23
 <211> 19
 <212> PRT
 <213> E. Coli

<400> 23
 Met Ile Glu Arg Glu Leu Gly Asn Trp Lys Asp Phe Ile Glu Val Met
 1 5 10 15
 Leu Arg Lys

<210> 24
 <211> 180
 <212> DNA
 <213> E. Coli

<400> 24
 aaaggagacg cttatgtttc gttggggcat catatttctg gttatcgcgt taatcgccgc 60
 cgcacttggg ttggtggtc tggccggtac cgctgcaggc gcagctaaaa ttgtctttgt 120
 cgctcgggatt attctgttcc tggtagagtt gttcatgggc cgaaaacgac cctagatttc 180

<210> 25
 <211> 53
 <212> PRT
 <213> E. Coli

<400> 25
 Met Phe Arg Trp Gly Ile Ile Phe Leu Val Ile Ala Leu Ile Ala Ala
 1 5 10 15

Ala Leu Gly Phe Gly Gly Leu Ala Gly Thr Ala Ala Gly Ala Ala Lys
 20 25 30
 Ile Val Phe Val Val Gly Ile Ile Leu Phe Leu Val Ser Leu Phe Met
 35 40 45
 Gly Arg Lys Arg Pro
 50

<210> 26
 <211> 226
 <212> DNA
 <213> E. Coli

<400> 26
 atacggagat atcatcatgg gcaaattagg tgaaaacggt ccgcttctta tcgataaagc 60
 cgtagatttc atggcatcaa gccaggcggt ccgggagtat ctgaaaaaac ttcttccccg 120
 taacgcgatt ccgtccggaa taccgatga aagcgtgccg ttatatctac aacgtctgga 180
 gtattatcgt cggctttatc ggccgaagca ggtagagggg cagtaa 226

<210> 27
 <211> 69
 <212> PRT
 <213> E. Coli

<400> 27
 Met Gly Lys Leu Gly Glu Asn Val Pro Leu Leu Ile Asp Lys Ala Val
 1 5 10 15
 Asp Phe Met Ala Ser Ser Gln Ala Phe Arg Glu Tyr Leu Lys Lys Leu
 20 25 30
 Pro Pro Arg Asn Ala Ile Pro Ser Gly Ile Pro Asp Glu Ser Val Pro
 35 40 45
 Leu Tyr Leu Gln Arg Leu Glu Tyr Tyr Arg Arg Leu Tyr Arg Pro Lys
 50 55 60
 Gln Val Glu Gly Gln
 65

<210> 28
 <211> 189
 <212> DNA
 <213> E. Coli

<400> 28
 gagtagttaa catgaagcgg agtagaacgg aagtggggcg ctggcgcatg cagcgtcagg 60
 ctagccgacg taaatcgcgt tggcttgagg ggcaatcgcg ccgaaatatg cgtatccaca 120
 gcatcaggaa gtgcattcta aacaaacagc gtaactcggt attgtttgcg atctacaata 180
 tctaaatgt 189

<210> 29
 <211> 57
 <212> PRT
 <213> E. Coli

<400> 29
 Met Lys Arg Ser Arg Thr Glu Val Gly Arg Trp Arg Met Gln Arg Gln

1	5	10	15
Ala Ser Arg Arg Lys Ser Arg Trp Leu Glu Gly Gln Ser Arg Arg Asn			
20	25	30	
Met Arg Ile His Ser Ile Arg Lys Cys Ile Leu Asn Lys Gln Arg Asn			
35	40	45	
Ser Leu Leu Phe Ala Ile Tyr Asn Ile			
50	55		

<210> 30
 <211> 117
 <212> DNA
 <213> E. Coli

<400> 30
 aacggaggca aataatgctg ggtaatatga atgtttttat ggccgtactg ggaataattt 60
 tatttttctgg ttttctggcc gcgtattttca gccacaaatg ggatgactaa tgaacgg 117

<210> 31
 <211> 31
 <212> PRT
 <213> E. Coli

<400> 31
Met Leu Gly Asn Met Asn Val Phe Met Ala Val Leu Gly Ile Ile Leu
1 5 10 15
Phe Ser Gly Phe Leu Ala Ala Tyr Phe Ser His Lys Trp Asp Asp
20 25 30

<210> 32
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide

<400> 32
 gcgcctcggt atcatccaaa atacg 25

<210> 33
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide

<400> 33
 gtcgcccagc caatgctttc agtcg 25

<210> 34
 <211> 25
 <212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 34

attgatcgca cacctgacag ctgcc

25

<210> 35

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 35

gttgtcaccc tggacctggt cgtac

25

<210> 36

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 36

tgaccgcgat ttgcacaaaa tgc

23

<210> 37

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 37

actcttaaatt ttcctatcaa aactcgc

27

<210> 38

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 38

ggtattttca gagattatga attgccg

27

<210> 39

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 39

tcacctctcc ttcgagcgct actgg

25

<210> 40

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 40

aatgctctcc tgataatggt aaactt

26

<210> 41

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 41

ggttagctcc gaagcaaaag ccggat

26

<210> 42

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 42

taattccttt caaatgaaac ggagc

25

<210> 43

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 43

ggactccctc attataatta ctgg

24

<210> 44

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 44

ctccttaaag aaggacatta gtctacg

27

<210> 45

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 45

attcacctta cctaatttga ttcttcc

27

<210> 46

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 46

ccatcgcttg acgttgcatc cacctgc

27

<210> 47

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 47

gtcggcgctcg tacgaatcaa ttgtgc

26

<210> 48

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 48

gcacaattga ttctgtacgac gccgac

26

<210> 49

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 49

taaggataat attgcagatc gtaag

25

<210> 50

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 50

atcatcaaac agcaacttgc cc

22

<210> 51

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 51

tgtccttctc ctgcaagaga attatt

26

<210> 52

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 52

gctaataata atgtcttttt cgctcc

26

<210> 53

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 53

gcttttgtga attaatttgt atatcgaagc g

31

<210> 54

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 54

tattaataacc ctctagattg agttaatc

28

<210> 55

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 55

cgatttacct cacttcacgc ctttcag

27

<210> 56

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 56

tgatcctgac ttaatgccgc aagttc

26

<210> 57

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 57

gcttatctcc ggcactctca gtggcttagc tcttgaagg

39

<210> 58

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 58

ttgtcacat ctcactttaa tcgtgctc

28

<210> 59

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 59

atattccacc agctatttgt tagtgaataa aagg

34

<210> 60

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 60

tgattaattt cgattatttt tcccggatgg

30

<210> 61

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 61

attagaaaca ggaagcccct cagtcgag

28

<210> 62

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 62

ttattttccc cggaagcaca ttcacttcac

30

<210> 63

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 63

tgatctattg cacaacgagg aagc

24

<210> 64

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 64

tgcttactca tcaaaagtag cgccagattc

30

<210> 65

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 65

taatcgacgg acgatagata attcctg

27

<210> 66

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 66

ccaatgtgtc gcctttttca actttccg

28

<210> 67

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 67

cgatttatga gaataaatac tcatttaagg gtg

33

<210> 68

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 68

aaatccgact ttagttacaa catac

25

<210> 69

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 69

gaccagacct tcttgatgat gggcac

26

<210> 70

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 70

cgacctcaat tccacgggat ctgg

24

<210> 71

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 71

atttagctgt agtaatcact cgccg

25

<210> 72

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 72

ggtctcctta ggccttatt gcg

23

<210> 73

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 73

cgcccatg ctgttcttat tattccc

27

<210> 74

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 74

tttatgacac ctgccactgc cgtc

24

<210> 75

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 75

ctgtcaagtt atctgtttgt taagtcaagc

30

<210> 76

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 76

gctgtgaagc acctgcgttg ctcattg

26

<210> 77

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 77

gctgtgaaac acctgcattt acggccaagg

30

<210> 78

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 78

ccgtggccgt aaatgcaggt gtttcacagc

30

<210> 79

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 79

ccttttcgcaa ttgactgaaa cac

23

<210> 80

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 80

ggctagaccg ggggtgcgcg

19

<210> 81

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 81

aaggtgggta ttacacctt agcg

24

<210> 82

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 82

gtcctctttg gggtaaattgt c

21

<210> 83

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 83

aatgctccgg tttcatgtca tc

22

<210> 84

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 84

tagttccttc tcacccggag

20

<210> 85

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 85

cacaagggcg ctttagtttg ttttccg

27

<210> 86

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 86

atcccctgag agtttaattt tcgtcaag

28

<210> 87

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 87

taattcgtcg taattcgtcc tcc

23

<210> 88

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 88

ctctgccttc ctgtttttgt tgtg

24

<210> 89

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 89

aaacgcattt gcaactgtcg gcgcttttcc

30

<210> 90

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 90

cttggttacct caaaaaatca cagtgtctcg

29

<210> 91

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 91

gcagtcggtg atgctggatt tgcctg

27

<210> 92

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 92

gttttttttac gggttaagccg caacgaccat tg

32

<210> 93

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 93

tagtagataa gtttttagata ac

22

<210> 94

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 94

taaaactgaa gttgccctga aaatg

25

<210> 95

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 95

tgatgagtgg ttctgcaaga gg

22

<210> 96

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 96

taaaagacag attacctggc ctg

23

<210> 97

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 97

cggactacct caaaataaag ctttatatac g

31

<210> 98

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 98

gtcatgatac cttgattaaa aaacaaacag c

31

<210> 99

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 99

ggctataatg cgcacataac ctcttg

26

<210> 100

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 100

aatcttttct ttttttttg ctaacgaata gcc

33

<210> 101

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 101

gtccaacttt ttggggtcag tacaaacttt g

31

<210> 102

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 102

taataacgcc gttattaaat agcctgcc

28

<210> 103

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 103

taagcaacgt ctgcttactg ccctc

26

<210> 104

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 104

gtgatggctt ctgataaaga taaatttata gcc

33

<210> 105

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 105

taacaggcta agaggggc

18

<210> 106

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 106

attgccactc ttcttgatca aataaccg

28

<210> 107

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 107

aatgcgtctg ttgataattc aaattagtc

29

<210> 108

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 108

tagccgtttt attcagtata gatttgcg

28

<210> 109

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 109

gttcgtcggg aacccgtttc agc

23

<210> 110

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 110

atggcttaaa gagaggtgcc

20

<210> 111

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 111

cgtactttaa agggagaatg ac

22

<210> 112

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 112

gtgcttcctc attatggtga cg

22

<210> 113

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 113

gaatggaggg agattacacg

20

<210> 114

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 114

ccttagtggg taaacgctta c

21

<210> 115

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 115

ctttcaggca gctaaggaaa g

21

<210> 116

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 116

caatatgtat tattgattga gtaaacggg

29

<210> 117

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 117

cctcttccag gaataatccc

20

<210> 118

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 118

cggaagcgg ttcacagatc

20

<210> 119

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 119

ctcgtaagtt tcgcagctta tta

23

<210> 120

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 120

tgaaattcct gtccgacagg

20

<210> 121

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 121

gcactaccgc aatgttattg c

21

<210> 122

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 122

gcttacccaa taaatagtta cacg

24

<210> 123

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 123

taaaacctgt cacaaatcac aaa

23

<210> 124

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 124

gtggcctgct tcaaactttc g

21

<210> 125

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 125

gtaaagtcta gcctggcggt tcg

23

<210> 126

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 126

taattctggt acgcctggca gatattttgc c

31

<210> 127

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 127

atcaacctca aaagggaaat cggg

24

<210> 128

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 128

taacttggtg taagccggat cgg

23

<210> 129

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 129

tgaagcatct atcgccggtt gcg

23

<210> 130

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 130

gattagaaat ccttttgaaa gcgcattg

28

<210> 131

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 131

cttattgggc accgcaatgg

20

<210> 132

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 132

cgaacacaat aaagatttaa ttcagcc

27

<210> 133

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 133

ctgatgctac tgtgtcaacg

20

<210> 134

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 134

aataatcaga catagcttag gc

22

<210> 135

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 135

gccgtgatgg ttttcgcgtt c

21

<210> 136

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 136

tatttttcctc ccgcgctaaa g

21

<210> 137

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 137

ttcagctgat gaccaccacg ctt

23

<210> 138

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 138

gagttgtcag agcaggatga ttc

23

<210> 139

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 139

tatctgcgct tatectttat gg

22

<210> 140

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 140

cctttacggt gataaccgtc gcg

23

<210> 141

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 141

ctgacaagcc tctcattctc ttgtc

25

<210> 142

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 142

gagaattatc gaggtccggt atc

23

<210> 143

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 143

ctacgcgtta gcgatagact gc

22

<210> 144

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 144

aggcttacta agaacaccag ggggagggga a

31

<210> 145

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 145

agtcataagc ttccccgctt actaagacta

30

<210> 146

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 146

cctcaaatcg gccataataa cc

22

<210> 147

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 147

taaacaccgt cgtcagaaat gc

22

<210> 148

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 148

tagactttta tccactttat tgctg

25

<210> 149

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 149

gtgtgccttt cggcgatatg gcgtg

25

<210> 150

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 150

cctttacgtg ggcggtgatt ttgtc

25

<210> 151

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 151

tagctttgct cctggatggt tgcc

24

<210> 152

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 152

gctgtaattt attcagcgtt tgtacatag

30

<210> 153

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 153

tcagtcaact cgctgcggcg tggtac

26

<210> 154

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 154

cttattgttg cttagttagg gtagtcac

28

<210> 155

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 155

cagtcagtct caggggagga gcaatc

26

<210> 156

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 156

tgaatgcaca ataaaaaaaaat cccgaccctg

30

<210> 157

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 157

agtcgcgcag tactcctctt accag

25

<210> 158

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 158

taatttctca tcaggcggct ctgc

24

<210> 159

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 159

taacattatc agcctgctga cggc

24

<210> 160

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 160

ggccgaattc gtaggtaca gaggtaag

28

<210> 161

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 161

ggccgatcc gtcattactg actggggcgg

30

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number
WO 02/060914 A3

(51) International Patent Classification⁷: **C12N 15/11**,
15/31, C07K 14/245, 16/12

(21) International Application Number: **PCT/US02/03147**

(22) International Filing Date: 31 January 2002 (31.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/266,402 1 February 2001 (01.02.2001) US

(71) Applicant (for all designated States except US): **THE GOVERNMENT OF THE UNITED STATES OF AMERICA**, as represented by **THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]**; National Institutes of Health, Office of Technology Transfer, 6011 Executive Building, Suite 325, Rockville, MD 20852-3804 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GOTTESMAN, Susan [US/US]**; 6400 Maiden Lane, Bethesda, MD 20817 (US). **STORZ, Gisela [US/US]**; 9012 Grant Street, Bethesda, MD 20817 (US). **REPOILA, Francis [FR/US]**; 5015 Battery Lane, Apt. 602, Bethesda, MD 20814 (US). **WASSARMAN, Karen [US/US]**; 9918 Thornwood Road, Kensington, MD 20895 (US). **ROSENOW, Carsten [DE/US]**; 105 Livorno Way, Redwood Shores, CA 94065 (US).

(74) Agent: **ALTMAN, Daniel, E.**; Knobbe, Martens, Olson And Bear, LLP, 620 Newport Center Drive, 16th Floor, Newport Beach, CA 92660 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

(88) Date of publication of the international search report:
18 September 2003


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IDENTIFICATION OF SMALL RNAs AND ORFS FORM E. COLI AS MEDIATORS OF CELL AND INTERCELL REGULATION

WO 02/060914 A3

rprA

>



>

(57) Abstract: The invention relates to small RNAs and ORFs of E. coli as mediators of cell and intercell regulation.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 02/03147

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/11 C12N15/31 C07K14/245 C07K16/12		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, BIOSIS, EMBL		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL [Online] 29 January 1997 (1997-01-29) BLATTNER F.R.: "Escherichia coli K12 MG1655 section 122 of 400 of the complete genome" Database accession no. AE000232 XP002223290 nucleotides 4480-4620 & BLATTNER F.R. ET AL.: "The complete genome sequence of escherichia coli K-12" SCIENCE, vol. 277, no. 5331, 1997, pages 1453-1474, XP002069950 --- -/--	1
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "C" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 3 December 2002		Date of mailing of the international search report 04.03.2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer MONTERO LOPEZ B.

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WASSARMAN K M ET AL: "SMALL RNAS IN ESCHERICHIA COLI" TRENDS IN MICROBIOLOGY, ELSEVIER SCIENCE LTD., KIDLINGTON, GB, vol. 7, no. 1, January 1999 (1999-01), pages 37-45, XP001029095 ISSN: 0966-842X the whole document	1,32,57
A	--- AIXIA ZHANG ET AL.: "The OxyS regulatory RNA represses rpoS translation and binds the Hfq (HF-I) protein" THE EMBO JOURNAL, vol. 17, no. 20, 1998, pages 6061-6068, XP002223288 cited in the application abstract page 6061, left-hand column, paragraph 1 -right-hand column, paragraph 3 page 6062, left-hand column, paragraph 2 page 6062, right-hand column, last paragraph -page 6063, left-hand column, paragraph 1 page 6065, left-hand column, last paragraph -page 6066, left-hand column, paragraph 4	1,32,57
P,X	--- KAREN M. WASSARMAN ET AL.: "Identification of novel small RNAs using comparative genomics and microarrays" GENES & DEVELOPMENT, vol. 15, no. 13, 1 July 2001 (2001-07-01), pages 1637-1651, XP002223289 the whole document -----	1,32,57

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 02/03147

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1, 32 and partially 57

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1, 32 and partially 57

Polynucleotide comprising Candidate #8; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

2. Claims: 2, 33 and partially 57

Polynucleotide comprising Candidate #12; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

3. Claims: 3, 23 and partially 57

Polynucleotide comprising Candidate #14; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

4. Claims: 4, 35 and partially 57

Polynucleotide comprising Candidate #22; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

5. Claims: 5, 36 and partially 57

Polynucleotide comprising Candidate #24; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

6. Claims: 6, 37 and partially 57

Polynucleotide comprising Candidate #25; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

7. Claims: 7, 38 and partially 57

Polynucleotide comprising Candidate #26; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

8. Claims: 8, 39 and partially 57

Polynucleotide comprising Candidate #27; antibody binding to

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

it and use of the polynucleotide as mediator of cell or intercell regulation

9. Claims: 9, 40 and partially 57

Polynucleotide comprising Candidate #31; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

10. Claims: 10, 41 and partially 57

Polynucleotide comprising Candidate #38; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

11. Claims: 11, 42 and partially 57

Polynucleotide comprising Candidate #40; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

12. Claims: 12, 43 and partially 57

Polynucleotide comprising Candidate #41-I; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

13. Claims: 13, 44, and partially 57

Polynucleotide comprising Candidate #41-II; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

14. Claims: 14, 45 and partially 57

Polynucleotide comprising Candidate #43; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

15. Claims: 15, 46 and partially 57

Polynucleotide comprising Candidate #52-I; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

16. Claims: 16, 47 and partially 57

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Polynucleotide comprising Candidate #52-11; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

17. Claims: 17, 48 and partially 57

Polynucleotide comprising Candidate #55-1; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

18. Claims: 18, 48 and partially 57

Polynucleotide comprising Candidate #55-11; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

19. Claims: 19, 50 and partially 57

Polynucleotide comprising Candidate #61; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

20. Claims: 20, 26, 51 and partially 57

Polynucleotide comprising Candidate #9; polypeptide encoded by candidate #9; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

21. Claims: 21, 27, 52 and partially 57

Polynucleotide comprising Candidate #17; polypeptide encoded by candidate #17; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

22. Claims: 22, 28, 53 and partially 57

Polynucleotide comprising Candidate #28; polypeptide encoded by candidate #28; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

23. Claims: 23, 29, 54 and partially 57

Polynucleotide comprising Candidate #36; polypeptide encoded by candidate #36; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

24. Claims: 24, 30, 55 and partially 57

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Polynucleotide comprising Candidate #49; polypeptide encoded by candidate #49; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

25. Claims: 25, 31, 56 and partially 57

Polynucleotide comprising Candidate #50; polypeptide encoded by candidate #50; antibody binding to it and use of the polynucleotide as mediator of cell or intercell regulation

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number
WO 2002/060914 A3

(51) International Patent Classification⁷: **C12N 15/11**,
15/31, C07K 14/245, 16/12

(21) International Application Number:
PCT/US2002/003147

(22) International Filing Date: 31 January 2002 (31.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/266,402 1 February 2001 (01.02.2001) US

(71) Applicant (for all designated States except US): **THE GOVERNMENT OF THE UNITED STATES OF AMERICA**, as represented by **THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; National Institutes of Health, Office of Technology Transfer, 6011 Executive Building, Suite 325, Rockville, MD 20852-3804 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GOTTESMAN**, Susan [US/US]; 6400 Maiden Lane, Bethesda, MD 20817 (US). **STORZ**, Gisela [US/US]; 9012 Grant Street, Bethesda, MD 20817 (US). **REPOILA**, Francis [FR/US]; 5015 Battery Lane, Apt. 602, Bethesda, MD 20814 (US). **WASSARMAN**, Karen [US/US]; 9918 Thornwood Road, Kensington, MD 20895 (US). **ROSENOW**, Carsten [DE/US]; 105 Livorno Way, Redwood Shores, CA 94065 (US).

(74) Agent: **ALTMAN**, Daniel, E.; Knobbe, Martens, Olson And Bear, LLP, 620 Newport Center Drive, 16th Floor, Newport Beach, CA 92660 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*

(88) Date of publication of the international search report:
18 September 2003

(48) Date of publication of this corrected version:
8 July 2004

(15) Information about Correction:
see PCT Gazette No. 28/2004 of 8 July 2004, Section II


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IDENTIFICATION OF SMALL RNAS AND ORFS FORM E. COLI AS MEDIATORS OF CELL AND INTERCELL REGULATION

WO 2002/060914 A3

rprA

>



>

(57) Abstract: The invention relates to small RNAs and ORFs of E. coli as mediators of cell and intercell regulation.

This Page Blank (uspiw)